Official Protocol Title:  
NCT number:  [STUDY_ID_REMOVED] 
Document Date:  01-Jun-2018A Phase 3, Multicenter, Randomized, Double-blind, Active 
Comparator-controlled Study to Evaluate the Safety, 
Tolerability, and Immunogenicity of V114 Followed by 
[CONTACT_63492]™23 Eight Weeks Later in 
Adults Infected with HIV (PNEU–WAY)
PRODUCT: V114 1
PROTOCOL/AMENDMENT N O.:018-01
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
Title Page
THIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING 
TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK 
SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC., NJ, U.S.A. 
(MSD).
Protocol Title: A Phase 3, Multicenter, Randomized, Double -blind, Active Comparator -
controlled Study  to Evaluate the Safet y, Tolerability , and Immunogenicit y of V114 Followed 
by [CONTACT_63492]™23 Eight Weeks Later in Adults Infected with HIV 
(PNEU –WAY)
Protocol Number: 018-01
Compound Number: V114
Sponsor Name:
[CONTACT_19519] & Dohme Corp., a subsidiary  of [COMPANY_006] & Co., Inc.
(hereafter referred to as the Sponsor or MSD)
Legal Registered Address:
One [COMPANY_006] Drive
[PO_BOX]
Whitehouse Station, New Jersey , [ZIP_CODE] -0100, U.S.A.
Regulatory Agency Identifying Number(s):
IND
EudraCT14977
2017 -001909 -32
Approval Date: 01-JUN -[ADDRESS_1141800]: V114 2
PROTOCOL/AMENDMENT N O.:018-01
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
Sponsor Signatory
Typed Name:
[CONTACT_1641]:Date
Protocol -specific Sponsor c ontact information can be found in the Investigator Study
File Binder (or equivalent).
Investigator Signatory
I agree to conduct this clinical study in accordance with the design outlined in this protocol 
and to abide b y all provisions of this protocol.
Typed Name:
[CONTACT_1641]:Date 
  04Y2KD 
  05KG4L
PRODUCT: V114 3
PROTOCOL/AMENDMENT N O.:018-01
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
PROTOCOL AMENDMENT S UMMARY OF CHANGES
Amendment: 01
Overall Rationale for the Amendments:
The primary  purpose of this amendment is to remove the collection of medical device incidents from the protocol (removal of S ection 
6.1.1, Section 8.4.8, and Appendix 4). The implementation of the FDA guidance for reporting events related to co mbination products 
has been delay ed until January  2020. Therefore, the current protocol is not within the scope of medical device reporting requ irements. 
Other clarifications and editorial revisions were also made as shown in the Summary  of Changes Table b elow.
Summary of Changes Table:
Section # and Name [CONTACT_11029]  
2.2.1 V114 and Pneumococcal Disease Licensure dates for Prevnar 13™ were added to 
the third paragraph.
Revisions were made in the fourth par agraph to 
better align with the cited literature.Revisions made for accuracy .
[IP_ADDRESS] Immunogenicit y Endpoints The following revision has been made to the first 
sentence (revision in bold ):
Sera from participants will be used to measure 
vaccine -induced, serot ype-specific OPA and IgG 
responses for all 15 seroty pes (1, 3, 4, 5, 6A, 6B, 
7F, 9V, 14, 18C, 19A, 19F, 22F, 23F,and 33F) 
included in V114 using the Multiplexed 
Opsonophagocy tic Assay (MOPA) assay  and 
pneumococcal electrochemiluminescence 
(PnECL ) assay .Revision made for accuracy . 
  04Y2KD 
  05KG4L
PRODUCT: V114 4
PROTOCOL/AMENDMENT N O.:018-01
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
Section # and Name [CONTACT_11029]  
6.1.1 Medical Devices
8.4.8 Medical Device Incidents 
(Including Malfunctions)
10.4 Appendix 4: Medical Device 
Incidents: Definition and Procedures for 
Recording, Evaluating, Follow -up, and 
ReportingSections removed. The implementation of the FD A 
guidance for reporting events related 
to combination products has been 
delay ed until January  2020. 
Therefore, the current protocol is not 
within the scope of medical device 
reporting requirements.
6.5Concomitant Therap y The following addition has been made (in bold ) 
to #3:
3.Participants should not receive s ystemic 
corticosteroids ( prednisone equivalent of ≥20 
mg/day  for ≥14consecutive day s) starting from 
30days prior to through [ADDRESS_1141801]: V114 5
PROTOCOL/AMENDMENT N O.:018-01
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
Section # and Name [CONTACT_11029]  
8.1.[ADDRESS_1141802] Questionnaire
1.3Schedule of Activities (SoA)The text in Section 8.1.10 was revised as 
follows:
Original : All participants will be contact[INVESTIGATOR_530] b y 
telephone at Month [ADDRESS_1141803] Questionnaire. Data to be reported on 
this q uestionnaire will include SAEs and/or an y 
updates to concomitant medications, nonstudy  
vaccinations, and previously  reported safet y 
information.
Revised : Site personnel will contact [CONTACT_63494] a Telephone Contact [CONTACT_63495] b y the Sponsor. Data to be reported 
from this discussion will include SAEs and/or 
any updates to concomitant medications, 
nonstudy  vaccinations, and previously  reported 
safet y information.
The revised text was also added to t he SoA.Revisions were made to clarify  the 
process for administering the 
telephone contact [CONTACT_63496]. 
  04Y2KD 
  05KG4L
PRODUCT: V114 6
PROTOCOL/AMENDMENT N O.:018-01
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
Section # and Name [CONTACT_11029]  
8.4.1 Time Period and Frequency  for 
Collecting AE, SAE, and Other Reportable 
Safety  Event InformationThe following text was deleted from the second 
paragraph in this section:
All AEs, SAEs, and other reportable safety  
events must be reported by  [CONTACT_252341]/randomization to the first 
vaccination and from the day of each vaccination 
through 14 day s (42 day s for live atten uated 
vaccines) postvaccination.  SAEs must also be 
reported throughout the duration of the 
individual’s participation in the study , regardless 
of whether or not related to the Sponsor’s 
product.Live attenuated vaccines are not 
provided as part of the stu dy.
8.5Treatment of Overdose The definition of overdose was revised as 
follows:
Original: In this study , an overdose is any  dose 
higher than 1 dose of an y individual study  
vaccine during the individual’s participation in 
the study .
Revised: In this study , an overdose is the 
administration of more than [ADDRESS_1141804]: V114 7
PROTOCOL/AMENDMENT N O.:018-01
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
Section # and Name [CONTACT_11029]  
9.4.1 Immunogenicit y Endpoints The following sentence was added:
Immune responses will be measured fo r each of 
the following seroty pes contained in V114: 1, 3, 
4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 
23F, and 33F.Text added to clarify  that immune 
responses will be tested for the 
seroty pes contained in V114 and not 
for all of the PNEUMOVAX™23 
seroty pes.
9.6.2 Statistical Methods for Safet y 
Analy ses, Table 5 Tier 2 safety  endpoint was revised as follows 
(changes in bold ):
“Any SAE and vaccine -related AE” was changed 
to “Any vaccine -related SAE ”Table was revised to align with 
safet y analy sis plan and text under 
Tier [ADDRESS_1141805]: V114 8
PROTOCOL/AMENDMENT N O.:018-01
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
Table of Contents
PROTOCOL AMENDMENT S UMMARY OF CHANGES ............................................... 3
1 PROTOCOL SUMMARY ............................................................................................ 15
1.1 Synopsis ................................................................................................................. 15
1.2 Schema .................................................................................................................. 19
1.3 Schedule of Activities (SoA) ................................................................................ 20
2 INTRODUCTION .......................................................................................................... 25
2.1 Study Rationale .................................................................................................... 25
2.2 Background .......................................................................................................... 25
2.2.1 V114 and Pneumococcal Disease ................................................................ 25
2.2.2 Preclinical and Clinical Studies ................................................................... 26
2.2.3 Information on Other Study -related Therap y.............................................. 26
[IP_ADDRESS] Prevnar 13™ ...................................................................................... 26
[IP_ADDRESS] PNEUMOVAX™23 .......................................................................... 27
2.3 Benefit/Risk Assessment ...................................................................................... 28
3 HYPOTHESIS, OBJECTIV ES, AND ENDPOINTS ................................................. 29
4 STUDY DESIGN ............................................................................................................ 31
4.1 Overall Design ...................................................................................................... 31
4.2 Scientific Rationale for Study Design ................................................................ .32
4.2.1 Rationale for Endpoints ............................................................................... 33
[IP_ADDRESS] Immunogenicit y Endpoints ................................................................ 33
[IP_ADDRESS] Safety  Endpoints ................................................................................ 33
[IP_ADDRESS] Future Biomedical Research .............................................................. 33
4.2.2 Rationale for the Use of Comparator/Placebo ............................................. 34
4.3 Justification for Dose ........................................................................................... 34
4.4 Beginning and End of Study Definition ............................................................. 34
4.4.1 Clinical Criteria for Early Study Termination ............................................. 34
5 STUDY POPULATION ................................................................................................ 35
5.1 Inclusion Criteria ................................................................................................ .35
5.2 Exclusion Criteria ................................................................................................ 36
5.3 Lifestyle Considerations ...................................................................................... 38
5.4 Screen Failures ..................................................................................................... 38
5.5 Participant Replacement Strategy ...................................................................... 38
6 STUDY INTERVENTION ............................................................................................ 38
6.1 Study Intervention(s) Administered ................................................................... 38
6.2 Preparation/Handling/Storage/Accountability ................................................. [ADDRESS_1141806]: V114 9
PROTOCOL/AMENDMENT N O.:018-01
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
6.2.1 Dose Preparation .......................................................................................... 40
6.2.2 Handling, Storage, and Accountability ........................................................ 40
6.3 Measures to Minimize Bias: Randomization and Blinding .............................. 40
6.3.1 Intervention Assignment.............................................................................. 40
6.3.2 Stratification ................................................................................................ .41
6.3.3 Blinding ........................................................................................................ 41
6.4 Study Intervention Compliance .......................................................................... 41
6.5 Concomitant Therapy .......................................................................................... 42
6.5.1 Rescue Medications and Supportive Care ................................................... 42
6.6 Dose Modification (Escalation/Titration/Other) ............................................... [ADDRESS_1141807] to Follow Up ................................................................................................ .44
8 STUDY ASSESSMENTS AN D PROCEDURES ........................................................ 45
8.1 Administrative and General Procedures ........................................................... 46
8.1.1 Informed Consent ......................................................................................... 46
[IP_ADDRESS] General Informed Consent ................................................................ .46
[IP_ADDRESS] Consent and Collection of Specimens for Future Biomedical 
Research ............................................................................................. 47
8.1.2 Inclusion/Exclusion Criteria ........................................................................ [ADDRESS_1141808] ..................................................................... 47
8.1.4 Medical History ........................................................................................... 47
8.1.5 Prior and Concomitant Medications Review ............................................... 47
[IP_ADDRESS] Prior Medications ............................................................................... 47
[IP_ADDRESS] Concomitant Medications .................................................................. 48
8.1.6 Assignment of Screen ing Number ............................................................... 48
8.1.7 Assignment of Treatment/Randomization Number ..................................... 48
8.1.8 Study  Intervention Administration .............................................................. 48
[IP_ADDRESS] Timing of Dose Administration ......................................................... [ADDRESS_1141809] Questionnaire ................................................................ 50
8.1.11 Discontinuation and Withdrawal ................................................................ .50
[IP_ADDRESS] Withdrawal From Future Biomedical Research ................................ 50
8.1.12 Participant Blinding/Unblinding .................................................................. [ADDRESS_1141810]: V114 10
PROTOCOL/AMENDMENT N O.:018-01
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
8.1.13 Calibration of Equipment ............................................................................. 51
8.2 Immunogenicity Assessments ............................................................................. 51
8.2.1 Multiplex Opsonophagocytic Assay (MOPA) ............................................. 52
8.2.2 Electrochemiluminescence (ECL) ............................................................... [ADDRESS_1141811] ............................................................................................. 53
8.3.3 HIV Serology , CD4+ T -cell count, and Plasma HIV RNA Testing ............ 53
8.3.4 Body Temperature Measurement ................................................................ .53
8.3.5 Safety  Assessments and Use of the eVRC ................................................... 54
8.3.6 Clinical L aboratory  Assessments ................................................................ .54
8.4 Adverse Events (AEs), Serious Adverse Events (SAEs), and Other 
Reportable Safety Events .................................................................................... 55
8.4.1 Time Period and Frequency  for Collecting AE, SAE, and Other Reportable 
Safety  Event Information ............................................................................. 55
8.4.2 Method of Detecting AEs, SAEs, and Other Reportable Safet y Events ......57
8.4.3 Follow -up of AE, SAE, and Other Reportable Safety  Event Information ...57
8.4.4 Regulatory  Reporting Requirements for SAE ............................................. 57
8.4.5 Pregnancy  and Exposure During Breastfeeding .......................................... 57
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualify ing as 
AEs or SAEs ................................................................................................ [ADDRESS_1141812] ............................................................................ 58
8.5 Treatment of Overdose ........................................................................................ 58
8.6 Pharmacokinetics................................................................................................ .58
8.7 Pharmacodynamics .............................................................................................. 58
8.8 Future Biomedical Research Sample Collection ............................................... 58
8.9 Planned Genetic Analysis Sample Collection .................................................... 58
8.10 Biomarkers ........................................................................................................... 59
8.11 Medical Resource Utilization and Health Economics ....................................... 59
8.12 Visit Requirements ............................................................................................... 59
8.12.1 Screening ...................................................................................................... 59
8.12.2 Treatment Period/Vaccination Visit ............................................................ 59
8.12.3 Discontinued Participants Continuing to be Monitored in the Study .......... 59
9 STATISTICAL ANALYSIS PLAN ............................................................................. 59
9.1 Statistical Analysis Plan Summary..................................................................... 60
9.2 Responsibility for Analyses/In -house Blinding ................................................. 61
9.3 Hypotheses/Estimation ........................................................................................ [ADDRESS_1141813]: V114 11
PROTOCOL/AMENDMENT N O.:018-01
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
9.4.1 Immunogenicit y Endpoints .......................................................................... 62
9.4.2 Safety  Endpoints .......................................................................................... 62
9.5 Analysis Populations ............................................................................................ 63
9.5.1 Immunogenicit y Analysis Populations ........................................................ 63
9.5.2 Safety Anal ysis Populations ........................................................................ 63
9.6 Statistical Methods ............................................................................................... 64
9.6.1 Statistical Methods for Immunogenicit y Anal yses...................................... 64
9.6.2 Statistical Methods for Safet y Anal yses...................................................... 65
9.6.3 Demographic and Baseline Characteristics ................................................. 66
9.7 Interim Analyses .................................................................................................. 66
9.8 Multiplicity ........................................................................................................... 67
9.9 Sample Size and Power Calculations ................................................................ .67
9.9.1 Sample Size and Power for I mmunogenicity  Analy ses............................... 67
9.9.2 Sample Size and Power for Safet y Ana lyses............................................... 68
9.10 Subgroup Analyses ............................................................................................... 68
9.11 Compliance (Medication Adherence) ................................................................ .69
9.12 Extent of Exposure ............................................................................................... 69
10 SUPPORTING DOCUMENTA TION AND OPERATIONAL
CONSIDERATIONS ..................................................................................................... 70
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ........ [ADDRESS_1141814] for Clinical Trials ............................................................. 70
10.1.2 Financial Disclosure ..................................................................................... 72
10.1.3 Data Protection ............................................................................................. 72
[IP_ADDRESS] Confidentiality  of Data ...................................................................... 73
[IP_ADDRESS] Confidentiality  of Participant Records ............................................... 73
[IP_ADDRESS] Confidentiality  of IRB/IEC I nformation ............................................ 73
10.1.4 Committees Structure ................................................................................... 73
[IP_ADDRESS] Scientific Advisory  Committee .......................................................... 73
[IP_ADDRESS] Executive Oversight Committee ........................................................ 73
[IP_ADDRESS] External Data Monitoring Committee ............................................... 74
10.1.5 Publication Policy ........................................................................................ 74
10.1.6 Compliance with Study  Registration and Results Posting Requirements ...74
10.1.7 Complian ce with Law, Audit, and Debarment ............................................ 75
10.1.8 Data Qualit y Assurance ............................................................................... 75
10.1.9 Source Documents ....................................................................................... 76
10.1.10 Study  and Site Closure ................................................................................. 76
10.2 Appendix 2: Clinical Laboratory Tests .............................................................. [ADDRESS_1141815]: V114 12
PROTOCOL/AMENDMENT N O.:018-01
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting ............................................................... 78
10.3.1 Definition of AE .......................................................................................... 78
10.3.2 Definition of SAE ........................................................................................ 79
10.3.3 Additional Events Reported ......................................................................... 80
10.3.4 Recording AE and SAE ............................................................................... 80
10.3.5 Reporting of AE, SAE, and Other Reportable Safety  Events to the Sponsor 85
10.4 Append ix 4: Medical Device Incidents: Definition and Procedures for 
Recording, Evaluating, Follow -up, and Reporting ........................................... 87
10.5 Appendix 5: Contraceptive Guidance and Pregnancy Testing ........................ 88
10.5.1 Definitions .................................................................................................... 88
10.5.2 Contraception Requirements ........................................................................ 89
10.5.3 Pregnancy  Testing ........................................................................................ 90
10.6 Appendix 6: Collection and Management of Specimens for Future 
Biomedical Research ............................................................................................ 91
10.7 Appendix 7: Country -specific Requirements .................................................... 96
10.8 Appendix 8: Abbreviations ................................................................................. [ADDRESS_1141816]: V114 13
PROTOCOL/AMENDMENT N O.:018-[ADDRESS_1141817] OF TABLES
Table 1 Study  Interventions .......................................................................................... 39
Table 2 Approximate Blood Volumes Drawn b y Stud y Visit and by [CONTACT_63498] ...46
Table 3 Reporting Time Periods and Time Frames for Adverse Events and Other 
Reportable Safet y Events ................................................................................. 56
Table 4 Analy sis Strategy  for Immunogenicit y Variables ............................................ 65
Table 5 Analy sis Strategy for Safety  Parameters Following Each Vaccination ........... 66
Table 6 Within -Group 95% CI s for Vary ing Hy pothetical OPA GMTs and IgG GMCs 
and Vary ing Standard Deviations with [ADDRESS_1141818]: V114 14
PROTOCOL/AMENDMENT N O.:018-[ADDRESS_1141819]: V114 15
PROTOCOL/AMENDMENT N O.:018-01
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
1 PROTOCOL SUMMARY
1.1 Syno psis
Protocol Title: A Phase 3, Multicenter, Randomized, Double -blind, Active Comparator -
controlled Study  to Evaluate the Safet y, Tolerability , and Immunogenicit y of V114 Followed by 
[CONTACT_63492]™23 Eight Weeks Later in Adults Infected with HIV (PNEU –
WAY)
Short Title: Safet y and Immunogenicit y of V114 in Adults I nfected with HIV
Acronym: PNEUmococcal Conjugate Vaccine Trials :V114 -018 ( PNEU –WAY)
Hypotheses, Objectives ,and Endpoints :
The following objectives and endpoints will be evaluated in pneumococcal vaccine -naïve adults 
≥18 y ears of age infected with HIV (with CD4+ T -cell count ≥50 cells/µL and plasma HIV RNA 
<50,000 copi[INVESTIGATOR_014]/mL tested at Screening [Visit 1]).
Primary  Objectives Primary  Endpoints
-Objective: To evaluate the safet y and 
tolerability  of V114 an d Prevnar 13™ with 
respect to the proportion of participants with 
adverse events (AEs) within each vaccination 
group separatel y.Following vaccination with V114 or 
Prevnar 13™:
-Solicited injection -site AEs from Day 1 
through Day 5 postvaccination
-Solic ited sy stemic AEs from Day 1 through 
Day 14 postvaccination
-Vaccine -related serious adverse events 
(SAEs) from Day 1 to Week 8
-Objective: To evaluate the serot ype-specific 
opsonophagocy tic activity (OPA) Geometric 
Mean Titers (GMTs) and I mmunoglobulin G 
(IgG) Geometric Mean Concentrations 
(GMCs) at 30 day s postvaccination (Day  30) 
with V114 and Prevnar 13™ within each 
vaccination group separately . -Seroty pe-specific OPA and IgG responses for 
the [ADDRESS_1141820]: V114 16
PROTOCOL/AMENDMENT N O.:018-01
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
Secondary  Objectives Secondary  Endpoints
-Objective: To evaluate the safet y and 
tolerability  of PNEUMOVAX™23 
administered 8 weeks following V114 and of 
PNEUMOVAX™23 administered 8 weeks 
following Prevnar 13™ with respect to the 
proportion of participants with AEs within 
each vaccination group separately . Following vaccination with 
PNEUMOVAX™23:
-Solicited injection -site AEs from Day  1 
through Day 5 postvaccination 
-Solicited sy stemic AEs from Day  1 through 
Day 14 postvaccination 
-Vaccine -related SAEs from Week 8 to 
Mont h 6
-Objective: To evaluate the serot ype-specific 
OPA GMTs and IgG GMCs at 30 day s 
postvaccination with PNEUMOVAX™23 
(Week 12) for participants administered V114 
and separatel y for participants administered 
Prevnar 13™ 8 weeks before receipt of 
PNEUMOVAX ™23. -Seroty pe-specific OPA and IgG responses for 
the 15 serotypes in V114 at Week 12
Overall Desig n:
Study  Phase Phase [ADDRESS_1141821] participant’s last 
study -related telephone call or visit.
For purposes of analy sis and reporting, the overall study  
ends when the Sponsor rec eives the last serology  assay  
result. 
  04Y2KD 
  05KG4L
PRODUCT: V114 17
PROTOCOL/AMENDMENT N O.:018-01
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
Number of Participant s:
Approximately  300participants will be randomized ,with approximately 150participants in each 
intervention group .
Intervention Groups and Du ration :
Intervention 
Group s Intervention 
Group
Name [CONTACT_63562].Vaccination 
Regimen Use
V114V114Refer to 
IBSingle 
doseIM Single Dose 
at Visit 2
(Day 1)Experimental
PNEUMOVAX™23Refer to 
product
labelingSingle 
doseIMSingle Dose 
at Visit 4 
(Week 8)Experimental
Prevnar 
13™Prevnar 13™Refer to 
product 
labelingSingle 
doseIM Single Dose 
at Visit 2
(Day  1)Experimental
PNEUMOVAX™23Refer to 
product 
labelingSingle 
doseIMSingle Dose 
at Visit 4 
(Week 8)Experimental
IB=Investigator’s Brochure; IM=intramuscular .
Total 
Number2intervention groups
Duration of 
ParticipationEach participant will participate in the study  for approximately  6 months from 
the time the participant signs the Informed Consent F orm (ICF) through the final 
contact. 
Study Governance Committees:
Steering Committee No
Executive Oversight Committee Yes
Data Monitoring Committee Yes
Clinical Adjudication Committee No
Study  governance considerations are outlined in Appendix 1. 
  04Y2KD 
  05KG4L
PRODUCT: V114 18
PROTOCOL/AMENDMENT N O.:018-01
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
Study Accepts Healthy Volunteers :No
A list of abbreviations used in this document can be found in Appendix 8. 
  04Y2KD 
  05KG4L
PRODUCT: V114 19
PROTOCOL/AMENDMENT N O.:018-[ADDRESS_1141822]: V114 20
PROTOCOL/AMENDMENT N O.:018-01
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
1.3 Schedule of Activities (SoA)
Study Period Screening Intervention Follow -up
CommentsVisit Number : [ADDRESS_1141823]
Scheduled Time: Screening Day 1 Day 15 Day 30 Week 8 Week 10 Week 12 Month 6
Visit Window:[ADDRESS_1141824] be 
available before enrollment into 
the study at Visit 2 (Day 1).
Administrative and General 
Procedures
Informed Consent X Consent must be obtained 
before any study procedures.
Informed Consent for Future Biomedical 
ResearchX Informed consent for future 
biomedical research samples 
must be obtained before the 
blood sample (DNA sample) is 
collected.
Assignment of Screening Number X
Inclusion/Exclusion Criteria X X
Serum for HIV Serology X
Blood sample for CD4+ T -cell count X X X
Blood sample for plasma HIV RNA 
testingX X X
Medical History X X The participant’s medical 
history for the [ADDRESS_1141825] X
Prior/Concomitant Medication and Non -
Study Vaccination ReviewX X X X X X X
V114 or Prevnar 13™ Administration 
(Blinded) X At Visit 2 (Day 1), participants 
will receive either a single dose 
ofV114 or a single dose of 
Prevnar 13™ .  
  04Y2KD 
  05KG4L
PRODUCT: V114 21
PROTOCOL/AMENDMENT N O.:018-01
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
Study Period Screening Intervention Follow -up
CommentsVisit Number : [ADDRESS_1141826]
Scheduled Time: Screening Day 1 Day 15 Day 30 Week 8 Week 10 Week 12 Month 6
Visit Window:[ADDRESS_1141827] be 
available before enrollment into 
the study at Visit 2 (Day 1).
PNEUMOVAX™23 Administration 
(Open -label) X At Visit 4 (Week 8), all 
participants will receive a 
single dose of 
PNEUMOVAX™23 . Study 
vaccine should be removed 
from the refrigerator no more 
than 1 hour before vaccination. 
The time of removal and time 
of vaccination should be 
documented in the participant ’s 
chart.
Provide electronic Vaccination Report 
Card (eVRC) X All participants will be 
provided an eVRC at Visit 2 
(Day 1) to record AEs and body 
temperature measurements. 
Instructions for using the eVRC 
will be reviewed with the 
participant.
Review eVRC data with participant X X X X
Collect eVRC from participant X
Complete the Telephone Contact 
[CONTACT_93288] X Site personnel will contact 
[CONTACT_823566] 
a Telephone Contact 
[CONTACT_63500]. Data to be reported 
from this discussion will 
include SAEs and/or any 
updates to concomitant 
medications, nonstudy 
vaccinations , and previously 
reported safety information. 
  04Y2KD 
  05KG4L
PRODUCT: V114 22
PROTOCOL/AMENDMENT N O.:018-01
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
Study Period Screening Intervention Follow -up
CommentsVisit Number : [ADDRESS_1141828]
Scheduled Time: Screening Day 1 Day 15 Day 30 Week 8 Week 10 Week 12 Month 6
Visit Window:[ADDRESS_1141829] be 
available before enrollment into 
the study at Visit 2 (Day 1).
Safety Procedures
Complete Physical Examination X To be performed by [CONTACT_823567].
Directed Physical Examination X To be performed by [CONTACT_823567].
Pregnancy Test – if applicable X X A pregnancy test consistent 
with local requirements 
(sensitive to at least 25 IU beta 
human chorionic gonadotropin, 
β-hCG) must be performed 
before administration of the 
study vaccine in females who 
are of reproductive potential. 
Urine or serum tests can be 
used, and results must be 
negative before vaccination can 
occur.
Body Temperature Measurement Before 
VaccinationX X Each participant's body 
temperature must be taken 
before vaccination. Participants 
who present with fever (oral or 
tympanic temperature ≥100.4°F 
[≥38.0°C]; axillary or temporal 
temperature ≥99.4°F [≥37.4°C]; 
or rectal temperature ≥101.4°F 
[≥38.6°C]) will have the 
vaccination delayed until fever 
is resolved for [ADDRESS_1141830]: V114 23
PROTOCOL/AMENDMENT N O.:018-01
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
Study Period Screening Intervention Follow -up
CommentsVisit Number : [ADDRESS_1141831]
Scheduled Time: Screening Day 1 Day 15 Day 30 Week 8 Week 10 Week 12 Month 6
Visit Window:[ADDRESS_1141832] be 
available before enrollment into 
the study at Visit 2 (Day 1).
AE Monitoring X X X X X X X X AEs (serious and nonserious) 
are to be reported from Days 1 
through 14 following each 
vaccination. SAEs and deaths 
are to be reported throughout 
the duration of the participant’s 
study participation.
AEs (serious and nonserious) 
that occur after the consen t is 
signed but before 
allocation/randomization are 
also to be reported 
(Section 8.4.1). 
  04Y2KD 
  05KG4L
PRODUCT: V114 24
PROTOCOL/AMENDMENT N O.:018-01
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
Study Period Screening Intervention Follow -up
CommentsVisit Number : [ADDRESS_1141833]
Scheduled Time: Screening Day 1 Day 15 Day 30 Week 8 Week 10 Week 12 Month 6
Visit Window:[ADDRESS_1141834] be 
available before enrollment into 
the study at Visit 2 (Day 1).
Immunogenicity Procedures
Serum for immunogenicity assays 
(including retention serum)X X X Blood samples must be 
collected before study 
vaccination when applicable.
After completion of 
opsonophagocytic (OPA) and 
electrochemiluminescence 
(ECL) testing, serum samples 
will be stored to conduct any 
additional study -related testing 
as required by [CONTACT_63503] . 
Leftover sera from the study 
may be used for the 
development and/or validation 
of pneumococcal assays after 
completion of all study -related 
immunogenicity testing; this 
applies only to sera received 
from randomized study 
participants who provided 
consent f or future biomedical 
research .
Future Biomedical Research
Blood (DNA) for Future Biomedical 
ResearchX Collected from randomized 
participants who provided 
consent for future biomedical 
research (See Section 8. 8)
aWhen scheduling the Telephone Contact (Day 15), Visit 3 (Day 30), and Visit 4 (Week 8), and the Telephone Contact (Month 6), “Day 1” is the date of Visit [ADDRESS_1141835] (Week 10) and Visit 5 (Week 12), “Day 1” is the date of Visit [ADDRESS_1141836]: V114 25
PROTOCOL/AMENDMENT N O.:018-01
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
2 INTRODUCTION
[COMPANY_006] Sharp & Dohme Corp. (MSD )is developi[INVESTIGATOR_63464] 15 -valent 
pneumococcal conjugate vaccine (PCV) (referred to as V114) for prevention of 
pneumococcal disease caused by  [CONTACT_528866]. V114 contains the 
13 seroty pes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19F, 19A, 23F) present in the licensed 
vaccine Prevnar 13™ (pneumococcal 13 -valent conjugate vaccine [diphtheria CRM 197
protein], Wy eth Pharmaceuticals, a subsidiary  of [COMPANY_007], I nc., Philadelphia, PA) , plus 2 
additional seroty pes (22F, 33F).
2.1 Study Rationale
Individuals infected with the human immunodeficiency  virus ( HIV) are at an increased risk 
of invasive pneumococcal disease (IPD) compared to uninfected individuals. Currently, 
treatment guidelines in many countries recommend the use of a PCV as part of a proposed 
immunization regimen for individuals infected with H IV [Centers for Disease Control and 
Prevention (CDC) 2012] [Castiglia P. 2014] .  
This clinical study  is designed to evaluate the safety , tolerability , and immunogenicity  of 
V114 and Prevnar 13™ in adults (≥18 y ears of age) infected with HIV (CD4+ T -cell count 
≥50 cells/µL  and a plasma HIV ribonucleic acid (RNA) value <50,000 copi[INVESTIGATOR_014]/mL  prior to 
study  entry ) who have not received a pneumococcal vaccine (vaccine -naïve). This study  will 
also describe the safe ty and tolerability  of PNEUMOVAX™23 (pneumococcal vaccine, 
polyvalent [23-valent ], MSD )when administered 8 weeks after receipt of either V114 or 
Prevnar 13™ and the immune responses to the 15 seroty pes contained in V114 following 
PNEUMOVAX™23 administrati on. The data from this study  will contribute to the overall 
safet y database and immunogenicity profile of V114 to support initial licensure in adults.
2.2 Background
2.2.1 V114 and Pneumococcal Disease  
Refer to the Investigator’s Brochure (IB) for V114 for more detailed background, including 
information on pneumococcal disease burden.
Streptococcus pneumoniae is a significant cause of disease worldwide, with clinical 
manifestations including pneumonia, meningitis, otitis media, sinusitis, and sepsis. Adults 
with comorbid conditions, in particular immunocompromised individuals, have a higher 
incidence of IPD mo rbidity  and mortalit y in all age groups compared to adults without the 
comorbid conditions [Lexau, C. A., et al 2005] . 
Currently  licensed pneumococcal conjugate vaccines (eg, Prevnar™, Sy nflorix™, and 
Prevnar 13™) were first implemented in infant immunization programs in many  countries 
worldwide. Prevnar™ was first licensed in 2000 and later replaced b y Prevnar 13™ in 2009 
for the European Union and in 2010 for the [LOCATION_002] . Although Prevnar 13™ is 
indicate d for children and adults, Sy nflorix™ is only  indicated for children up to [ADDRESS_1141837]: V114 26
PROTOCOL/AMENDMENT N O.:018-01
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
seroty pes contained in the vaccines in children who were targeted b y the vaccinat ion 
programs and unvaccinated individuals from other age groups (herd protection) [Centers for 
Disease Con trol and Prevention 2008] [Ruckinger, S., et al 2009] [Farrell, D. J, et al 2007] 
[Pi[INVESTIGATOR_63466], Tamara, et al 2010] [L exau, C. A., et al 2005] [Metlay, J. P., et al 2006] [Whitney , 
Cynthia G., et al 2003] [Moore, M. R., et al 2015] [L epoutre, A., et al 2015 ] [Weiss, S., et al 
2015] [Martinelli, D., et al 2014] [Guevara, M., et al 2016] [Waight, P. A., et al 2015] 
[Jokinen, J., et al 2015] [Palmu, A. A., et al 2015] [Wagenvoort, G. H., et al 2016] . 
Prevnar 13™ was also shown to be efficacious against vaccine -type nonbacteremic 
pneumococcal pneumon ia and IPD in adults ≥65 years of age [Bonten, M. J., et al 2015] . 
These stud y results were the basis of the recommendation from the ACI P for the sequential 
administration of Prevnar 13™ followed at least 1 2 months later by [CONTACT_63506]™23 in 
adults ≥65 y ears of age [Tomczy k, S., et al 2014] [Kobay ashi, M., et al 2015] .
Although cases of IPD have decreased following implementa tion of PCVs, an increase in 
IPD caused b y serotypes not covered b y currently  available vaccines has been observed. 
V114 contains 2 additional serot ypes (22F, 33F) compared with Prevnar 13™. The selection 
of 22F and 33F was primarily based on epi[INVESTIGATOR_823560] [ADDRESS_1141838] common seroty pe 
not included in Prevnar 13™ in adults ≥18 y ears of age, causing 13% of I PD cases. 
Seroty pe 33F is associated with an additional 5 % of I PD cases [Moore, M. R., et al 2015] . 
Data from the [LOCATION_008] also showed that , in 2013/2014, 22F and 33F are frequent 
seroty pes in adults ≥65 years of age, accounting for approximately  10% and 4% of IPD cases 
in that age group, respectively  [Waight, P. A., et al 2015] . Data from [ADDRESS_1141839] common seroty pes 
causing IPD[European Centre for Disease Prevention and Control 2016] .
The serot ypes included in V114 will provide broad coverage of the leading seroty pes 
associated with pneumococcal disease worldwide. V114 is designed to meet continuing 
medical and public health needs for PCVs globally, as well as to address the emergence of 
pneumococcal disease caused by  [CONTACT_823568]. V114 is 
designed to offer broader seroty pe coverage than Prevnar 13™ against pneumococcal disease 
in both pediatric and adult populations.
2.2.2 Preclinical and Clinical Studies
Refer to the IB f or information on completed pre clinical and clinical studies conducted with 
V114.
2.2.3 Information on Other Study -related Therapy
[IP_ADDRESS] Prevnar 13™
Refer to approved labeling for detailed background information on Prevnar 13™. 
  04Y2KD 
  05KG4L
PRODUCT: V114 27
PROTOCOL/AMENDMENT N O.:018-01
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
Prevnar 13™ contains all of the pneumococcal seroty pes included in Prevnar™ (4, 6B, 9V, 
14, 18 C, 19F, 23F) plus 6 additional serotypes (1, 3, 5, 6A, 7F, and 19A).
The adult indication was approved based on immune responses elicited b y Prevnar 13™ in 
comparison with PNEUMOVAX™23. A placebo -controlled clinical efficacy  trial 
(Community Acquired Pneum onia I mmunization Trial in Adults [CAPi[INVESTIGATOR_34172] ]) evaluated the 
efficacy  of Prevnar 13™ against pneumococcal pneumonia and IPD in immunocompetent 
adults ≥65 y ears of age. Results from CAPi[INVESTIGATOR_63468] 13™ was 45.6% (95%
confidence interval [ CI]:21.8% to62.5%) efficacious against vaccine -type nonbacteremic 
pneumococcal pneumonia and 75.0% ( 95% CI: 41.4% to90.8%) efficacious against vaccine -
type IPD in adults ≥65 years of age [Bonten, M. J., et al 2015] .
Prevnar 13™ was studied in individuals infected with HIV in 2 open -label, single -arm, 
descriptive studies. In one study, 3 doses of Prevnar 13™ were administered 6 months apart 
to adults ≥18 y ears of age infected with HIV (CD4+ T -cell count of ≥200 cells/µL  and HIV 
viral load of <50,000 copi[INVESTIGATOR_014]/mL ). All participants had previousl y received 
PNEUMOVAX™[ADDRESS_1141840] dose [Penaranda, M., et al 
2010] . In the second study , 3 doses of Prevnar 13™ were administered 1 month apart to 
individuals ≥6years of age infected wi th HIV with CD4+ T -cell counts ≥200 cells/µL , and 
HIV viral load <50,000 copi[INVESTIGATOR_014]/mL who had not previously  been vaccinated with a 
pneumococcal vaccine. For all vaccine serot ypes antibody  responses were numericall y higher 
after the first dose compared to pre vaccination and generall y comparable following the first, 
second and third dose [Bhorat, A. E., et al 2015] .
Prevnar™ and Prevnar 13™ are also known as Prevenar™ and Prevenar 13™ in many  
countries outside of the [LOCATION_002]; these vaccines arereferred to as Prevnar™ and 
Prevnar 13™ throughout this document.
[IP_ADDRESS] PNEUMOVAX™23
Refer to approved labeling for detailed background information on PNEUMOVAX™23.
PNEUMOVAX™[ADDRESS_1141841] important 
seroty pes causing disease in adults (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 
17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F). The formulation is not adjuvanted and no 
carrier protein is used . 
In the [LOCATION_002], PNEUMOVAX™23 is recommended by  [CONTACT_63509] P for routine use in 
immunocompetent adults ≥[ADDRESS_1141842] 1 y ear after 
Prevnar 13™ [Kobay ashi, M., et al 20 15]. It is also recommended for use in adults aged 19 
through 64 years of age with underly ing medical conditions that increase the risk for serious 
pneumococcal infection. These conditions include, but are not limited to, chronic heart 
disease, chronic lun g disease (including chronic obstructive pulmonary  disease, emph ysema, 
and asthma), diabetes mellitus, alcoholism, chronic liver disease (including cirrhosis), and 
cigarette smoking [Centers for Disease Control and Prevention 2010] . 
  04Y2KD 
  05KG4L
PRODUCT: V114 28
PROTOCOL/AMENDMENT N O.:018-01
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
PNEUMOVAX™23 is also recommended in immunocompromised adults ≥19 y ears of age; 
in this population, a dose of PNEUMOVAX™23 is recommended ≥8weeks following a 
dose of Prevnar 13™ [Kobay ashi, M., et al 2015] . Many  countries follow similar age -based 
and/or risk -based recommendations for the use of PNEUMOVAX™23 [Castiglia P. 2014] .
2.3 Benefit/Risk Asse ssment
It cannot be guaranteed that participants in c linical studies will directly  benefit from 
treatment during participation, as clinical studies are designed to provide information about 
the safet y and effectiveness of an investigational vaccine .
Approximately  50% of participants will receive Prevnar 13™, the standard of care, as the 
active comparator in this study . V114 is expected to provide comparable immune responses 
to Prevnar 13™ for the shared seroty pes while providing additional coverage for the 
2seroty pes (22F , 33F) unique to V114. I t is unknown if the investigational V114 will have 
the same benefit as Prevnar 13™. All participants will also receive PNEUMOVAX™[ADDRESS_1141843] 
additional seroty pes.
Additional details regardin g specific benefits and risks for participants participating in this 
clinical study  may  be found in the accompanyi ng IB and Informed Consent Form ( ICF). 
  04Y2KD 
  05KG4L
PRODUCT: V114 29
PROTOCOL/AMENDMENT N O.:018-01
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
3 HYPOTHESIS, O BJECTIVES ,AND ENDPOINTS
The following objectives and endpoints will be evaluated in pneumococcal vaccine -naïve 
adults ≥18 y ears of age infected with HIV (with CD4+ T -cell count ≥50 cells/µL  and plasma 
HIV RNA <50,000 copi[INVESTIGATOR_014]/mL  tested at Screening [Visit 1]).
Objectives Endpoints
Primary
•Objective: To evaluate the safet y and 
tolerability  of V114 and Prevnar 13™ 
with respect to the proportion of 
participants with adverse events
(AEs) within each vaccination group 
separately .Following vaccination with V114 or 
Prevnar 13™:
•Solicited injection -site AEs from 
Day 1 through Day 5 postvaccination
•Solicited sy stemic AEs from Day 1 
through Day 14 postvaccination
•Vaccine -related serious adverse 
events ( SAEs ) from Day 1 to Week 8
•Objective: To evaluate the serot ype-
specific opsonophagocy tic activity  
(OPA) Geometric Mean Titers 
(GMTs) andImmunoglobulin G (IgG)
Geometric Mean Concentrations 
(GMCs) at 30 day s postvaccination 
(Day  30) with V114 and Prevnar 13™
within each vaccination group 
separately .•Seroty pe-specific OPA and IgG 
responses for the 15 serotypes in 
V114 at Day 30
Secondary
•Objective: To evaluate the safet y and 
tolerability  of PNEUMOVAX™23 
administered 8 weeks following V114 
and of PNEUMOVAX™23 
administered 8 weeks following 
Prevnar 13™ with respect to the 
proportion of participants with AEs
within each vaccination group 
separately .Following vaccination with 
PNEUMOVAX™23 :
•Solicited injection -site AEs from Day  
1 through Day 5 postvaccination 
•Solicited sy stemic AEs from Day  1 
through Day 14 postvaccination 
•Vaccine -related SAEs from Week [ADDRESS_1141844]: V114 30
PROTOCOL/AMENDMENT N O.:018-01
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
Objectives Endpoints
•Objective: To evaluate the serot ype-
specific OPA GMTs and IgG GMCs 
at 30 day s postvaccination with 
PNEUMOVAX™23 (Week 12) for 
participants administered V114 and 
separately for participants 
administered Prevnar 13™ 8 weeks 
before receipt of 
PNEUMOVAX™23 .•Seroty pe-specific OPA and IgG 
responses for the 15 serotypes in 
V114 at Week 12
Tertiary /Exploratory
•Objective: To evaluate the serot ype-
specific OPA GMTs and IgG GMCs 
at 30 day s postvaccination (Day  30)
with V114 compared with Prevnar 
13TM.•Seroty pe-specific OPA and IgG 
responses for the 15 serotypes in 
V114 at Day 30
•Objective: To evaluate the serot ype-
specific OPA GMTs and IgG GMCs 
at 30 day s postvaccination with 
PNEUMOVAX™23 (Week 12) for 
participants administered V114 
compared with participants 
administered Prevnar 13™ 8 weeks 
before receipt of 
PNEUMOVAX™23 .•Seroty pe-specific OPA and IgG 
responses for the 15 serotypes in 
V114 at Week 12
•Objective: To evaluate the serot ype-
specific Geometric Mean Fold Rise s
(GMFR s)and proportions of 
participants with a ≥4-fold rise from 
prevaccination (Day  1) to 30 day s 
postvaccination (Day  30) for both 
OPA and IgG responses for 
participants administered V114 and 
separately  for participants 
administered Prevnar 13™.  •Seroty pe-specific OPA and IgG 
responses for the [ADDRESS_1141845]: V114 31
PROTOCOL/AMENDMENT N O.:018-01
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
Objectives Endpoints
•Objective: To evaluate the serot ype-
specific GMFRs and proportions of 
participants with a ≥4-fold rise from 
prevaccination (Day  1) to 30 day s 
postvaccination with 
PNEUMOVAX™23 (Week 12) for 
both OPA and IgG responses for 
participant s administered V114 and 
separately  for participants 
administered Prevnar 13™ 8 weeks 
before receipt of 
PNEUMOVAX™23 .•Seroty pe-specific OPA and IgG 
responses for the 15 serotypes in 
V114 at Day 1 and Week 12
4 S TUDY DESIGN
4.1 Overall Design
Approximately  300 individuals will be randomly  assigned in a 1:1 ratio to receive either 
V114 (150 participants) or Prevnar 13™ (150 participants) on Visit 2 (Day 1).  
Randomization will be stratified b y CD4+ T -cell count as follows:
•Stratum 1: CD4+ T -cell count ≥50 to <200 cells/µL
•Stratum 2: CD4+ T -cell count ≥200 to <500 cells/µL
•Stratum 3: CD4+ T -cell count ≥500 cells/µL .
At least 50% of participants will be enrolled into Stratum 2.  
All participants will also receive a single dose of PNEUMOVAX™ 23 at Visit 4 (Week 8).
Participants will be followed for local and s ystemic AEs through Day  14 following each 
vaccination. Information for SAEs and deaths, regardless of whether the events are 
considered to be vaccine -related b y the investigator, will be collected from the time consent 
is signed through completion of participation in the study. An external Data Monitoring 
Committee (DMC) will conduct a periodic review of safet y and tolerability data for the adult 
V114 Phase [ADDRESS_1141846]: V114 32
PROTOCOL/AMENDMENT N O.:018-01
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
Blood samples for i mmunogenicity  assay s will be drawn immediately before V114 or 
Prevnar 13™ vaccination at Visit 2 (Day  1), at 30 day s postvaccination at Visit 3 (Day  30), 
and 30 day s after PNEUMOVAX™23 vaccination at Visit 5 (Week 12).
After completion of OPA and electroch emiluminescence (ECL )testing, serum samples will 
be stored to conduct an y additional study -related testing as required by [CONTACT_63510]. Leftover sera from the stud y ma y be used for the development and/or validation 
of pneumococcal as says after completion of all study -related immunogenicity  testing; this 
applies only  to sera received from randomized study  participants who provided consent for 
future biomedical research . 
Specific procedures to be performed during the study , as well as their prescribed times and 
associated visit windows, are outlined in the SoA in Section 1.3. Details of each procedure 
are provided in Section 8.
4.[ADDRESS_1141847] a documented CD4+ T -cell count ≥50 cells/µL  as well as plasma 
HIV RNA <50,000 copi[INVESTIGATOR_014]/mL  prior to study entry is intended to assess safety , tolerabilit y, 
and immunogenicit y in a population that is representative of individuals infected with HIV 
for whom vaccination with a pneumococcal conjugate vaccine is recommended. Excluding 
individuals with CD4+ T -cell count <50 cells/µL  or plasma HIV RNA ≥50,000 copi[INVESTIGATOR_014]/mL  is 
based on the priorit y of optimizing combination ART th erapy to increase the CD4+ T- cell 
count and decrease plasma HIV RNA rather than participating in a clinical trial.
Stratum [ADDRESS_1141848] been recently diagnose d with HIV or are not well -
controlled with CD4+ T -cell count values <200 cells/μL . CD4+ T -cell counts are an 
important measure of immune suppression and values <200 cells/μL  indicate significant 
immune suppression associated with decreased life expectancy  [World Health Organization 
2013] . With the availability  of combination ART, individuals infected with HIV live longer, 
maintain CD4+ T -cell count values above 200 cells/μL , and maintain low levels of blood 
plasma HIV RNA [World Health Organiza tion 2013] . Recent studies have shown that only  
approximately  15% of individuals with HI V infection have CD4+ T -cell count values <200 
cells/μL  [Young, J., et al 2012] such that the enrollment into this stratum will not have a 
minimum sample size.
Stratum 2 represents individuals infected with HIV with moderate immune suppression 
(CD4+ T- cell count values ≥200 cells/µL to <500 cells/µL ). Data in this population have 
been previousl y obtained with Prevnar 13™. A CD 4+ T -cell count of ≥200 cells/µL  to <500
cells/µL is being used in order to ensure that a sufficiently  large sample size of participants 
with moderate immune suppression is studied (excluding the possibility  that the majority  of 
individuals with CD4+ T -cell count of ≥500 cells/µL  will be enrolled). This stratum will 
represent at least 50% of the sample size. 
  04Y2KD 
  05KG4L
PRODUCT: V114 33
PROTOCOL/AMENDMENT N O.:018-[ADDRESS_1141849] immune suppression with 
CD4+ T -cell count values ≥500 cells/µL . This stratum will not have a minimum sample size.
4.2.1 Rationale for Endpoints
[IP_ADDRESS] Immunogenicity Endpoints
Sera from participants will be used to measure vaccine -induced, serot ype-specific OPA and 
IgG responses for all 15 seroty pes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 
and 33F) included in V114 using the Multiplexed Opsonophagocy tic Assay  (MOPA) assay  
and pneumococcal electrochemiluminescence (PnECL ) assay . 
Several studies have shown a positive correlation between serot ype-specific IgG antibody  
concentrations and O PA titers in children and adults [Centers for Disease Control and 
Prevention 2010] [Anttila, M., et al 1999] [Romero -Steiner, S., et al 1997] . OPA assesses 
levels of functional antibodies capable o f opsonizing pneumococcal capsular poly saccharides 
for presentation to phagocy tic cells for engulfment and subsequent killing, and therefore ,is 
considered an important immunologic surrogate for protection against I PD in adults. Note 
that no antibody  conce ntration or titer for either assay  has been defined as the threshold value 
that correlates with protection in adults.
Details on the immunogenicity  endpoints evaluated in this study  can be found in 
Section 9.4.1.
[IP_ADDRESS] Safety Endpoints
The safet y endpoints evalu ated in this study  were selected based on the product’s safet y 
profile demonstrated in previous studies, published data from marketed PCVs, and feedback 
received from regulatory  agencies during product development. The electronic Vaccination 
Report Card (e VRC) used to record AEs during the postvaccination periods, as defined in 
Section 8.1.9, was structured as recommended in the final Food and Drug Administration 
Patient Reported Outcome Guidance [U.S. Food and Drug Administration 2009] .  
Details on the safet y endpoints evaluated in this study  can be found in Section 8.3. 5and 
Section 9.4.2.
Details on AEs, including definitions and reporting requirements, can be found in 
Appendix 3.
[IP_ADDRESS] Future Biomedical Research
The Sponsor will conduct future biomedical r esearch on specimens for which consent was 
provided during this study . This research may  include genetic anal yses (DNA), gene 
expression profiling ( ribonucleic acid [ RNA ]), proteomics, metabolomics (serum, plasma),
and/or the measurement of other analy tes, depending on whi ch specimens are consented for 
future biomedical r esearch. 
  04Y2KD 
  05KG4L
PRODUCT: V114 34
PROTOCOL/AMENDMENT N O.:018-01
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
Such research is for biomarker testing to address emergent questions not described elsewhere 
in the protocol (as part of the main study ) and will only  be conducted on specimens from 
appropriatel y consented participants. The objective of collecting/retaining specimens for 
future biomedical r esearch is to explore and identify  biomarkers that inform the scientific 
understanding of diseases and/ or their therapeutic treatments. The overarching goal is to use 
such information to develop safer, more effective drugs/vaccines, and/or to ensure that 
participants receive the correct dose of the correct drug/vaccine at the cor rect time. The 
details of th is future biomedical r esearch substudy  are presented in Appendix 6.
4.2.2 Rationale for the Use of Comparator/Placebo
This study  utilizes Prevnar 13™ as the active comparator as this is the only PCV licensed in 
many  developed countries for use in adults and is t he standard of care in individuals with 
HIV.  Including the active comparator that is the current standard of care is expected to 
provide meaningful safety and immunogenicit y data against which the clinical performance 
of V114 may  be compared in HIV -infect ed participants.
Prevnar 13™ is approved for adults 18 y ears of age and older for the prevention of 
pneumococcal pneumonia and invasive disease caused by  13 S.pneumoniae serot ypes (1, 3, 
4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F).
Refer to approved labeling for detailed background information on Prevnar 13™.
4.[ADDRESS_1141850] immune response.
The doses of Prevnar 13™ and PNEUMOVAX™[ADDRESS_1141851] to follow -up (ie, the participant is unable to be contact[INVESTIGATOR_530] b y the 
investigator).
For purposes of analy sis and reporting, the overall study  ends when the Sponsor receives the 
last serology  assay  result.
4.4.[ADDRESS_1141852]: V114 35
PROTOCOL/AMENDMENT N O.:018-01
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
5 STUDY POPULATION
Male/Female participants infected with HIV of at least [ADDRESS_1141853] y:
1.Infected with HIV and CD4+ T -cell count ≥50 cells/µL  and plasma HIV RNA 
<50,000 copi[INVESTIGATOR_014]/mL tested at Screening (Visit 1).
2.Receiving combination ART for at least 6 weeks prior to study entry with no intended 
changes to combination ART t herap y for 3 months after randomization.
Demographics
3.Participant is Male or Female ≥18 y ears of age .
Female Participants
4.A female participant is eligible to participate if she is not pregnant (Appendix 5), not 
breastfeeding, and at least 1 of th e following conditions applies:
a.Not a woman of childbearing potential (WOCBP) as defined in Appendix 5.
OR
b.A WOCBP who agrees to use [ADDRESS_1141854]: V114 36
PROTOCOL/AMENDMENT N O.:018-01
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
5.2 Exclusion Criteria
Participants are excluded from the study if an y of the following criteria apply:
Medical Conditions
1.History  of opportunistic infections within [ADDRESS_1141855] vacc ination at Visit 2 
(Day  1).
2.History  of non -infectious acquired immune deficiency  syndrome -related illness such as 
Kaposi's sarcoma, wasting syndrome, or HIV -associated nephropath y.
3.*History  of active hepatitis with elevation in pretreatment aspartate trans aminase or 
alanine transaminase values >[ADDRESS_1141856] vaccination at Visit 2 (Day 1).
4.History  of IPD (positive blood culture, positive cerebrospi[INVESTIGATOR_63469], or positive 
culture at another sterile site) or known history  of other culture -positive pneumococcal 
disease within 3 y ears of Visit 2 (Day  1).
5.Known hy persensitivity  to any  component of pneumococcal pol ysaccharide vaccine, 
pneumococcal conjugate vaccine, or an y diphtheria toxoid -containing vac cine.
6.Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or 
history  of autoimmune disease (including but not limited to the autoimmune conditions 
outlined in the I nvestigator Trial File Binder for this study ).
7.Coagulation diso rder contraindicating intramuscular vaccinations.
8.*Recent febrile illness (defined as oral or t ympanic temperature ≥100.4°F [≥38.0°C]; 
axillary  or temporal temperature ≥99.4°F [≥37.4°C]; or rectal temperature ≥101.4°F 
[≥38.6°C]) or received antibiotic therapy  for an y acute illness occurring within 72 hours 
before receipt of study  vaccine.
9.History of malignancy  ≤[ADDRESS_1141857] vaccination 
at Visit 2 (Day  1).
Prior/Concomitant Therapy
11. Prior administration of any  pneumococcal vaccine or expected to receive any  
pneumococcal vaccine during the stud y outside of t he protocol.
12.Received s ystemic corticosteroids (prednisone equivalent of ≥20 mg/day ) for 
≥14consecutive day s and has not completed treatment at least [ADDRESS_1141858]: V114 37
PROTOCOL/AMENDMENT N O.:018-01
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
13.Received s ystemic corticosteroids exceeding ph ysiologic replacement doses 
(approximately  5 mg/day prednisone equivalent) within 14 da ys before vaccination.  
(Note : Topi[INVESTIGATOR_2855], ophthalmic, intra -articular or soft -tissue [eg, bursa, tendon steroid 
injections], and inhaled/nebulized steroids are permitted).
14.Receiving immunosuppressive therapy, including chemotherapeutic agents used to treat 
cancer or other conditions, and treatments associated with organ or bone marrow 
transplantation, or autoimmune disease.  
15.*Received an y licensed, non -live vaccine within t he 14 day s before receipt of an y study 
vaccine or is scheduled to receive an y licensed, non -live vaccine within 30 day s 
following receipt of an y study  vaccine. Exception : Inactivated influenza vaccine may  be 
administered but must be given at least [ADDRESS_1141859] 15 day s after receipt of an y study vaccine.
16.*Received an y live vaccine within [ADDRESS_1141860] within 30 day s of receipt of study  vaccine. Autologou s blood transfusions 
are not considered an exclusion criterion.
Prior/Concurrent Clinical Study Experience
18.Is currently  participating in or has participated in an interventional clinical study  with an 
investigational compound or device within 2 months of p articipating in this current stud y.
Other Exclusions 
19.Is breastfeeding
20.Is, at the time of signing informed consent, a user of recreational or illicit drugs or has 
had a recent history  (within the last y ear) of drug or alcohol abuse or dependence as 
assesse d by [CONTACT_43038] y investigator .
21.Has history  or current evidence of any  condition, therap y, lab abnormalit y, or other 
circumstance that might expose the participant to risk by [CONTACT_6231], 
confound the results of the study , or interfere with the participant’s participation for the 
full duration of the study .
22.Is or has an immediate family  member (eg, spouse, parent/legal guardian, sibling, or 
child) who is investigational site or Sponsor staff directly involved with this study.
For items with an asterisk (*), if the participant meets these exclusion criteria, the 
Day [ADDRESS_1141861]: V114 38
PROTOCOL/AMENDMENT N O.:018-01
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
5.3 Lifestyle Considerations
No lifesty le restrictions are required.
5.4 Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study, but 
are not subsequently randomized in the study . A minimal set of screen failure information is 
required to ensure transparent reporting of screen failure participants to meet the 
Consolida ted Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory  authorities . Minimal information includes demograph y, 
screen failure details, eligibility criteria, and any AEs or SAEs meeting reporting 
requirem ents as outlined in the data entry  guidelines.
5.5 Participant Replacement Strategy
A participant who withdraws from the stud ywill not be replaced .
6 STUDY INTERVENTION
Study  intervention is defined as an y investigational intervention (s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a study  participant according to 
the study  protocol.
Clinical supplies [V114, Prevnar13™, PNEUMOVAX™23 ] will be packaged to support 
enrollment .Clinical supplies will be affixed with a clinical label in accordance with 
regulatory  requirements.
6.1 Study Intervention(s) Administered 
  04Y2KD 
  05KG4L
PRODUCT: V114 39
PROTOCOL/AMENDMENT N O.:018-01
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
The study intervention (s) to be used in this study are outlined inTable 1.
Table 1 Study  Intervention s
Arm 
NameArm Type Intervention Name [CONTACT_63563](s)Dosage 
Level(s)Route 
of 
AdminVaccination 
RegimenUse IMP/
NIMPSourcing
V114 Experimental V114 Biological/Vaccine Sterile 
suspension 
(prefilled 
syringe)Refer to IB 0.5 mL IM Single Dose 
at Visit 2 
(Day 1)Experimental IMP Central
PNEUMOVAX™23 Biological/Vaccine Sterile solution 
(prefilled 
syringe)Refer to 
product 
labeling0.5mL IM Single Dose 
at Visit 4 
(Week 8)Experimental IMP Central
Prevnar 
13™Active 
ComparatorPrevnar 13™ Biological/Vaccine Sterile 
suspension 
(prefilled 
syringe)Refer to 
product 
labeling0.5 mL IM Single Dose 
at Visit 2 
(Day 1)Experimental IMP Central
PNEUMOVAX™23 Biological/Vaccine Sterile solution 
(prefilled 
syringe)Refer to 
product 
labeling0.5 mL IM Single Dose 
at Visit 4 
(Week 8)Experimental IMP Central
Admin=administration; IB =Investigator’s Brochure; IM =intramuscular; IMP = investigational medicinal product; NIMP = non-investigational medicinal 
product
The definition of IMP and NIMP is based on guidance issued by [CONTACT_63512]. Regional and/or country differences of the definition of IMP/NIMP 
may exist. In these circumstances, local legislation is followed.
All supplies indicated in Table 1will be provided per the “Sourcing ”column depending upon local country  operational requirements. 
Every  attempt should be made to source these supplies from a single lot/batch number .
Refer to Section 8.1.[ADDRESS_1141862]: V114 40
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
6.2 Preparation/Handling/Storage/Accountability
6.2.[ADDRESS_1141863] be stored 
in a secure, environmentally  controlled, and monitored (manual or automated) area in 
accordance with the labeled storage conditions with access limited to the investigator and 
authorized site staff.
The investigator, institution, or the head of the medical institution (where applicable) is 
responsible for stud y intervention accountability , reconciliation, and record maintenance (ie, 
receipt, reconciliation, and final disposition records).
For all stud y sites, the local country Sponsor personnel or designee will provide appropriate 
documentation that must be completed for dru g accountability  and return, or local discard 
and destruction if appropriate. Where local discard and destruction is appropriate, the 
investigator is responsible for ensuring that a local discard/destruction procedure is 
documented.
The study  site is respo nsible for recording the lot number, manufacturer, and expi[INVESTIGATOR_63470] y purchased product (if applicable) as per local guidelines unless otherwise 
instructed by  [CONTACT_1034].
The investigator shall take responsibility  for and shall take all steps to maintain appropriate 
records and ensure appropriate supply, storage, handling, distribution, and usage of stud y 
intervention s in accordance with the protocol and any applicable laws and regulations.
6.3 Measures to Minimize Bias: Randomization and Blinding
6.3.1 Intervention Assignment
Treatment allocation/randomization will occur centrally using an interactive response 
technology  (IRT) s ystem. There are 2study  intervention arms. Participant s will be assigned 
randomly  in a 1
:1ratio to V114 and Prevnar 13™ , respectivel y. 
  04Y2KD 
  05KG4L
PRODUCT: V114 41
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
6.3.2 Stratification
Treatment allocation/randomization will be stratified according to the following factors:
1. Stratum 1: CD4+ T -cell count ≥50 to <200
2. Stratum 2: CD4+ T -cell count ≥200 to <500
3.Stratum 3: CD4+ T -cell count ≥[ADDRESS_1141864] 50% of participants will be enrolled into Stratum 2 .
6.3.3 Blinding
A double -blinding technique will be used. V114and Prevnar 13™ will be prepared and/or 
dispensed by  [CONTACT_63513]. The 
participant and the investigator who is involved in the clinical evaluation of the participants 
will remain blinded to the group assignments.
Because the V114 and Prevnar 13™ have a different appearance, a member of the study site 
staff will be unblinded for the purpose sof receiving, maintaining, preparing and/or 
dispensing, and administering the sestudy vaccine s.PNEUMOVAX™23 will also be 
prepared and/or dispensed and administered b y unblinded study  site staff for consi stency  
even though it will be provided open -label in this study . In order to avoid bias, the unblinded 
study person nelwill have no further contact [CONTACT_63515] -related 
procedures/assessments after administration of study  vaccines, which includes all safet y 
follow -up procedures . Additionally , blinded site personnel will not be present in the exam 
room when study  vaccines are administered. Contact [CONTACT_63516] .
Blinded site personnel will be responsible for all safet y and immunogenicity follow -up 
procedures after vaccine administration.
An unblinded Clinical Resea rch Associate will monitor vaccine accountability  at the study  
site. All o ther Sponsor personnel or delegate(s) and [COMPANY_006] Research Laboratories emplo yees 
directly  involved with the conduct of this study  will remain blinded to the participant -level 
interven tion assignment .
See Section 8.1.12for a description of the method of unblinding a participant during the 
study  should such action be warranted.
6.4 Study Intervention Compliance
Interruptions from the protocol specified plan for V114 or Prevnar 13™ vaccinati on at 
Visit 2 (Day  1) and PNEUMOVAX™23 vaccination at Visit 4 (Week 8) require 
consultation between the investigator and the Sponsor and written documentation of the 
collaborative decision on participant management. 
  04Y2KD 
  05KG4L
PRODUCT: V114 42
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
6.5 Concomitant Therapy
Medications or vaccinatio ns specificall y prohibited in the exclusion criteria are not allowed
during the ongoing stud y. If there is a clinical indication for an y medication or vaccination 
specificall y prohibited, di scontinuation from study intervention may be required. T he 
investigator should discuss any questions regarding this with the Sponsor Clinical Director. 
The final decision on any supportive therap y or vaccination rests with the investigator and/or 
the participant’ s primary  physician. However, the decision to con tinue the participant on 
study  intervention requires the mutual agreement of the investigator, the Sponsor, and the 
participant.
Listed below (items 1 to 4) are specific restrictions for concomitant therapy or vaccination
during the course of the study :
1.Any administration of a non -study  pneumococcal vaccine is prohibited during the stud y.
2.Live and non -live vaccines may  only  be administered prior to or following the receipt of 
study  vaccine according to the time frames specified in Exclusion Criteria (Sectio n 5.2). 
Exception: Inactivated influenza vaccine may  be administered but must be given at least 
[ADDRESS_1141865] 15 day s after receipt of any  study  
vaccine.
3.Participants should not receive s ystemic corticosteroids ( prednisone equivalent of 
≥20mg/day  for ≥14 consecutive day s) starting from 30 day s prior to through 30 day s 
following vaccination . Note : Topi[INVESTIGATOR_2855], ophthalmic, intra -articular or soft -tissue (eg, bursa, 
tendon steroid injections), and inhaled/nebulized steroid s are permitted.
4.Participants should not receive s ystemic corticosteroids exceeding ph ysiologic 
replacement doses (prednisone equivalent dose >5 mg/day ) within 14 day s before any  
vaccination. Note : Topi[INVESTIGATOR_2855], ophthalmic, intra -articular or soft -tissue (eg, b ursa, tendon 
steroid injections), and inhaled/nebulized steroids are permitted.
Any deviation from the above requires consultation between the investigator and the Sponsor 
and written documentation of the collaborative decision on participant management.
6.5.1 Rescue Medications and Supportive Care
No rescue or supportive medications are specified to be used in this study.
6.6 Dose Modification (Escalation/Titration/Other)
No dose modification is allowed in this study .
6.[ADDRESS_1141866]: V114 43
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
6.8 Clinical Supplies Disclosure
This study  is blinded but supplies are provided open label; therefore, an unblinded 
pharmacist or unblinded qualified study  site personnel will be used to mainta in the blinding 
of study  staff who are directly  involved in the clinical evaluation of participants in the study . 
Study  intervention identity  (name, strength, or potency ) is included in the label text; random 
code/disclosure envelopes or lists are not prov ided.
The emergency  unblinding call center will use the intervention /randomization schedule for 
the study  to unblind participants and to unmask study  intervention identity . The emergency  
unblinding call center should only  be used in cases of emergency  (see
Section 8.1.1 2). In the 
event that the emergency unblinding call center is not available for a given site in this study , 
the central electronic intervention allocation/randomization sy stem (IRT) should be used to 
unblind participants and to unmask study  intervention identity . The Sponsor will not provide 
random code/disclosure envelopes or lists with the clinical supplies.
See Section 8.1.[ADDRESS_1141867] be collected through the participant’s last scheduled follow -
up, even if the participant has discontinued study intervention. Therefore, all participants 
who discontinue study intervention prior to completio n ofthe protocol -specified vaccination s
will still continue to participate in the study as specified in Section 1.3 and Section 8.12.3,
unless the participant withdraws consent (Section 7.2) .
Participants may  discontinue study  intervention at any  time for any reason or be d iscontinued 
from the study  intervention at the discretion of the investigator should an y untoward effect 
occur. In addition, a participant may  be discontinued from study  intervention by  [CONTACT_823569], the study plan is violated, or 
for administrative and/or other safet y reasons. Specific details regarding procedures to be 
performed at study  intervention discontinuation are provided in Section 8.1. 11. 
  04Y2KD 
  05KG4L
PRODUCT: V114 44
PROTOCOL/AMENDMENT N O.:018-[ADDRESS_1141868] be disconti nued from study  intervention but continue to be monitored in 
the study  for an y of the following reasons:
•The participant requests to discontinue study  intervention.
•The participant has a medical condition or personal circumstance which, in the 
opi[INVESTIGATOR_1101] t he investigator and/or Sponsor, placed the participant at unnecessary  risk 
from continued administration of study  intervention.
•The participant has a confirmed positive urine or serum pregnancy  test before 
vaccination with PNEUMOVAX™23 at Visit 4 (Week 8).
For participants who are discontinued from study  intervention but continue to be monitored 
in the study , see Section 1.3 and Section 8.12.3 for those procedures to be completed at each 
specified visit.
Discontinuation from study  intervention is “permanent.” Once a participant is discontinued, 
he/she shall not be allowed to restart stud y intervention .
7.[ADDRESS_1141869] ing withdrawal from future biomedical r esearch, are 
outlined in Section 8.1.11 .The procedures to be performed should a participant repeatedl y 
fail to return for scheduled visits and/or if the study site is unable to contact [CONTACT_63517] 7.3.
7.[ADDRESS_1141870] to Follow Up
If a participant fails to return to the clinic for a required study visit and/or if the site is unable 
to contact [CONTACT_2299], the following procedures are to be performed:
•The site must attempt to contact [CONTACT_31823] t and reschedule the missed visit. I f the 
participant is contact[INVESTIGATOR_530], the participant should be counseled on the importance of 
maintaining the protocol -specified visit schedule.
•The investigator or designee must make every  effort to regain contact [CONTACT_126534] (eg, telephone calls and/or a certified letter to the 
participant’s last known mailing address or locally equivalent methods). These 
contact [CONTACT_13140]’s medical record. 
  04Y2KD 
  05KG4L
PRODUCT: V114 45
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
•Note: A particip ant is not considered lost to follow -up until the last scheduled visit for 
the individual participant. The missing data for the participant will be managed via 
the prespecified statistical data handling and analysis guidelines.
8 STUDY ASSESSMENTS AN D PROCED URES
•Study  procedures and their timing are summarized in the SoA.
•Adherence to the stud y design requirements, including those specified in the SoA, is 
essential and required for study  conduct.
•The investigator is responsible for ensuring that procedures are conducted by  
[CONTACT_11399] y qualified or trained staff. Delegation of study site personnel 
responsibilities will be documented in the Investigator Stud y File Binder (or 
equivalent).
•All study -related medical decisions must be made by  [CONTACT_19427] a 
qualified phy sician .
•All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log 
to record details of all participants screened and to confirm eligibility  or record 
reasons for screening failure, as applicable.
•Additional evaluations/testing may  be deemed necessary  by [CONTACT_126535]. In some cases, such 
evaluation/testing may  be potentially  sensitive in nature (eg, HIV, Hepatitis C), and 
thus local regulations may require that additional informed consent be obtained from 
the participant. In these cases, such evaluations/testing will be performed in 
accordance with those regulat ions.
Table 2shows the approximate blood volumes drawn b y study visit and by [CONTACT_63520]. The 
maximum amount of blood collected from each participant at each stud y visit will not exceed 
[ADDRESS_1141871]: V114 46
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
Table 2 Approximate Blood Volumes Drawn b y Stud y Visit and by [CONTACT_63521] 1
(Screening)Visit 2
(Day 1)Visit 3
(Day 30)Visit 4
(Week 8)Visit 5
(Week 12)
Blood parameter Approximate Blood Volume (mL)
Serum for HIV serology 4 mL N/A N/A N/A N/A
Blood sample for CD4+ T -cell 
count 2 mL N/A 2 mL N/A 2 mL
Blood sample for plasma HIV 
RNA testing6 mL N/A 6 mL N/A 6 mL
Serum for immunogenicity assays 
(including retention serum)N/A 40 mL 40 mL N/A 40 mL
Blood (DNA) for Future 
Biomedical ResearchN/A 8.5 mL N/A N/A N/A
Expected total (mL) 12 mL 48.5 mL 48 mL N/A 48 mL
DNA = deoxyribonucleic acid; HIV = human immunodeficiency virus; N/A = not applicable; RNA = 
ribonucleic acid .
8.1 Administrative and General Procedures
8.1.1 Informed Consent
The investigator or medically  qualified designee (consistent with local requirements) must 
obtain documented consent from each potential participant prior to participating in a clinical 
study or future biomedical r esearch .If there are changes to the participant’s status during the 
study  (eg, health or age of majority  requirements), the investigator or medically  qualified 
designee must ensure the appropriate consent is in place.
[IP_ADDRESS] General Informed Consent
Consent must be docum ented by  [CONTACT_2299]’s dated signature [INVESTIGATOR_2394] a consent form along 
with the dated signature [CONTACT_63564].
A cop y of the signed and dated consent form should be given to the participant before 
participation in the study .
The initial I CF, any  subsequent revised written ICF, and an y written information provided to 
the participant must receive the Institutional Review Board/Independent Ethics Committee’s 
(IRB/IEC’s )approval/favorable opi[INVESTIGATOR_19349]. The participant should be 
informed in a timely  manner if new information becomes available that may be relevant to 
the participant’s willingness to continue participation in the study . The communication of 
this information will be provided and documented via a revised co nsent form or addendum to 
the original consent form that captures the participant’s dated signature.
Specifics about a stud y and the study population will be added to the consent form template 
at the protocol level. 
  04Y2KD 
  05KG4L
PRODUCT: V114 47
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
The informed consent will adhere to IRB/ IEC requirements, applicable laws and regulations, 
and Sponsor requirements .
[IP_ADDRESS] Consent and Collection of Specimens for Future Biomedical Research
The investigator or medically  qualified designee will explain the future biomedical r esearch 
consent to the part icipant, answer all of his/her questions, and obtain written informed 
consent before performin g any procedure related to the future biomedical research sub study . 
A cop y of the informed consent will be given to the participant.
8.1.2 Inclusion/Exclusion Criteria
All inclusion and exclusion criteria will be reviewed by [CONTACT_63522] a qualified 
physician to ensure that the participant qualifies for the study .
If the participant meets any  of the Exclusion Criteria with an asterisk (*), Visit 1 (Screening ) 
may be rescheduled for a time when these criteria are not met.
8.1.[ADDRESS_1141872] i nformation (including direct 
telephone numbers) to be used in the event of an emergency . The investigator or qualified 
designee will provide the participant with a participant identification card immediately after 
the participant provides written informed consent. At the time of intervention
allocation/randomization, site personnel will add the intervention/randomization number to 
the participant identification card.
The participant identification card also contains contact [CONTACT_19430] a healthcare provider can obtain information about study 
intervention in emergency situations where the investigator is not available.
8.1.4 Medical Histo ry
A medical history  will be obtained by  [CONTACT_823570] 2 (Day  1). The participant’s medical history  for the 5 y ears prior to 
Visit 2(Day  1) will be obtained to ensure that the participant satisfies the inclusion and 
exclusion criteria of the study . History  of tobacco use will a lso be collected for all 
participants.
8.1.5 Prior and Concomitant Medications Revi ew
[IP_ADDRESS] Prior Medications
The investigator or qualified designee will review and record prior vaccinations and 
medication staken b y the participant within 30days before the first dose of study  vaccin e at 
Visit 2 (Day  1). 
  04Y2KD 
  05KG4L
PRODUCT: V114 48
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
[IP_ADDRESS] Concomitant Medications
The investigator or qualified designee will record medication, if an y, taken by [CONTACT_63525] y.
New and/or concomitant medications taken after the first do se of stud y vaccination at Visit 2 
(Day  1) and non -study  vaccines received since Visit [ADDRESS_1141873] not be re -used for 
different participants.
Any participant who is screened multi ple times will retain the original screening number 
assigned at the initial screening visit. Specific details on the screening/rescreening visit 
requirements are provided in Section 8.12.1.
8.1.7 Assignment of Treatment/Randomization Numb er
All eligible particip ants will be randomly  allocated and will receive a 
treatment /randomization number. The treatment/randomization number identifies the 
participant for all procedures occurring after treatment allocation/randomization. Once a 
treatment /randomization number is assigned to a participant, it can never be re -assigned to 
another participant.
A single participant cannot be assigned more than 1 treatment /randomization number.
8.1.8 Study Intervention Administrati on
V114 or Prevnar 13™ will be administered at Visit 2 (Day  1). PNEUMOVAX™23 will be 
administered at Visit 4 (Week 8).
Study  vaccines should be removed from the refrigerator no more than 1 hour before 
vaccination. The time of removal and time of vaccination should be documented in the 
participant’s chart.
Unblinded study  personnel not otherwise involved in the conduct of the study  will prepare 
and administer V114, Prevnar 13™, or PNEUMOVAX™23 at the stud y site. 
PNEUMOVAX™[ADDRESS_1141874]: V114 49
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
resuspension . This action should be repeated, as necessary . If appearance is otherwise, the 
vaccine should not be administered.  The vaccine should not be used if the vaccine cannot be 
resuspended.
Study  personnel should follo w the preparation and administration instructions for 
Prevnar 13™ and PNEUMOVAX™[ADDRESS_1141875] labels.
Study  vaccine will be administered as a single 0.5 -mL intramuscular injection in the deltoid 
region of the participant’s arm .Vaccination information, such as Component I dentification 
Number and time of vaccination, must be recorded on the appropriate electronic case report 
form (eCRF ) per the Data Entry  Guidelines.
All safet y and immunogenicity assessments will be conducted b y blinded personnel, and the 
participant will be blinded to the intervention (ie, V114 or Prevnar 13™) received.
[IP_ADDRESS] Timing of Dose Administration
Vaccinations may  be administered at any  time of day , and without regard to timing of meals. 
Each participant's body temperature must be taken before each vaccine administration.  
Individuals who present with fever (oral or t ympanic temperature ≥100.4°F [≥38.0°C]; 
axillary  or temporal temperature ≥99.4°F [≥37.4°C]; or rectal temperature ≥101.4°F 
[≥38.6°C]) will have the vaccination delayed until fever is resolved for at least 72 hours.
The collection of blood samples and administration of pregnancy tests (if applicable) must be 
done before each vaccine administration. 
All participants will be obs erved for [ADDRESS_1141876] be performed b y blinded site personnel for all study  
vaccines (Section 1.3 and Section 6.3. 3).
8.1.[ADDRESS_1141877]
The eVRC was developed to be ad ministered electronically  via a hand -held device. This item 
was structured as recommended in the final Food and Drug Administration Patient Reported 
Outcome Guidance [U.S. Food and Drug Administration 2009] . The
investigator or delegate 
will train the participant in the use of the eVRC at Visit 2 (Day 1). 
Temperatures, injection -site reactions, vaccine -specific complaints, other complaints or 
illnesses, and concomitant medications or vaccinations will be recorde d on the eVRC as 
described in the Section 1.[ADDRESS_1141878] (Day  15), Visit 3 
(Day  30), Telephone Contact (Week 10), and Visit 5 (Week 12).
For the AEs outlined above, the investigator will use the information provided by [CONTACT_63526], and verball y at the time of eVRC review, to apply the 
appropriate assessment of intensity  and toxicity  as described in Appendix 3. 
  04Y2KD 
  05KG4L
PRODUCT: V114 50
PROTOCOL/AMENDMENT N O.:018-[ADDRESS_1141879] Questionnaire provided b y the Sponsor. Data to be reported from this 
discussion will include SAEs and/or an y updates to concomitant medications, nonstudy  
vaccinations, and previously  reported safet y information.
8.1.11 Discontinuation and Withdrawal
Participants who discontinue study  intervention prior to completion of the protocol -specified 
vaccinations should be encouraged to continue to be followed for all remaining stud y visits.
When a participant withdraws from participation in the study, all applicable activities 
scheduled for the final study  visit (Visit 5 [Week 12 ]
)should be performed if the participant 
can attend durin g the Day  [ADDRESS_1141880] activities should be performed (at the time of 
withdrawal). An y AEs that are present at the time of withdrawal should be followed in 
accordance with the safety requirements outlined in Section 8.4 .
[IP_ADDRESS] Withdrawal From Future Biomedical Resear ch
Participants may withdraw their consent for future biomedical r esearch. Participants may  
withdraw consent at an y time by  [CONTACT_823571] . If 
medical records for the main study  are still available, the investigator will contact [CONTACT_63527] ([EMAIL_1250]). 
Subsequently ,the participant's consent for future biom edical r esearch will be withdrawn. A 
letter will be sent from the Sponsor to the investigator confirming the withdrawal. It is the 
responsibility  of the investigator to inform the participant of completion of withdrawal. An y 
analyses in progress at the tim e of request for withdrawal or alread y performed prior to the 
request being received by [CONTACT_528879]. No new analys es would be generated after the request is received.
In the event that the medical records for the main study  are no longer available (eg, if the 
investigator is no longer required b y regulatory authorities to retain the main study records) 
or the specimens have been completel y anon ymized, there will no longer be a link between 
the participant’s personal information and their specimens. In this situation, the request for 
specimen withdrawal cannot be processed . 
8.1.12 Participant Blinding/Unblindi ng
STUDY INTERVENT ION IDENT IFICATION INFORMAT ION IS TO BE UNMASKED 
ONLY IF N ECESSARY FOR THE WELFARE OF THE PARTICIPANT. EVERY 
EFFORT SHOULD BE MADE NOT TO UNBLIND.
For emergency  situations where the investigator or medically  qualified designee (consistent 
with local requirements) needs to identify  the drug used by  a participant a nd/orthe dosage 
administered , he/she will contact [CONTACT_63529] t elephone and  
  04Y2KD 
  05KG4L
PRODUCT: V114 51
PROTOCOL/AMENDMENT N O.:018-[ADDRESS_1141881] for emergency  unblinding. As requested by  [CONTACT_2697] y 
qualified designee the emergency  unblinding call center will pro vide the information to 
him/her promptly  and report unblinding to the Sponsor. Prior to contact[CONTACT_126538] a participant’s treatment assignment, the 
investigator who is a qualified phy sician should make reasonable attempts to enter the 
intensity /toxicity  grade of the AEs observed, the relation to study  intervention, the reason 
thereof , etc., in the medical chart. If it is not possible to record this assessment in the chart 
prior to the unblinding, the un blinding should not be delay ed.
In the event that unblinding has occurred, the circumstances around the unblinding (eg, date, 
reason, and person performing the unblinding) must be documented promptly, and the 
Sponsor Clinical Director notified as soon as p ossible.
Once an emergency  unblinding has taken place, the principal investigator, site personnel, and 
Sponsor personnel may  be unblinded so that the appropriate follow -up medical care can be 
provided to the participant .
Participants whose treatment assign ment has been unblinded by [CONTACT_2697] y 
qualified designee and/or nonstudy  treating ph ysician should continue to be monitored in the 
study .Participants may  receive PNEUMOVAX™23 at Visit 4 (Week 8) after a benefit/risk 
assessment and consu ltation between the investigator/delegate and Sponsor.
Additionally , the investigator or medically  qualified designee must go into the I RT sy stem 
and perform the unblind in the I RT sy stem to update drug disposition. In the event that the 
emergency  unblinding call center is not available for a given site in this study , the IRT 
system should be used for emergency  unblinding in the event that this is required for 
participant safety .     
8.1.13 Calibration of Equipme nt
The investigator or qualified designee has the responsibility  to ensure that any  device or 
instrument used for a clinical evaluation/test during a clinica l study  that provides information 
about inclusion/exclusion criteria and/or safety or efficacy  parameters shall be suitably  
calibrated and /ormaintained to ensure that the data obtained is reliable and/or reproducible. 
Documentation of equipment calibration must be re tained as source documentation at the 
study  site.
8.2 Immunogenicity Assessmen ts
Sera from participants will be used to measure vaccine -induced OPA and IgG for serot ypes 
included in V114 and Prevnar 13™. These endpoints will be tested for all blood draws. 
Blood collection, storage and shipment instructions for serum samples will be pro vided in the 
operations/laboratory  manual. 
The MOPA will be used for measuring OPA GMTs. Opsonization of pneumococci for 
phagocy tosis is an important mechanism by  [CONTACT_63531]. The OPA assay  is a usef ul tool for assessing the protective function  
  04Y2KD 
  05KG4L
PRODUCT: V114 52
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
of serot ype-specific antibodies and therefore ,the immunogenicit y of pneumococcal vaccine 
formulations.
Measurement of serot ype-specific IgG will be measured using the PnECL  v2.0 assay  to 
assess the concentrati on of binding antibodies to capsular pol ysaccharide of S. pneumoniae
for the serot ypes included in the study  vaccines.
8.2.1 Multiplex Opsonophagocytic Assay (MOPA)
The MOPA, developed and published by  [CONTACT_63532] (Director of the United 
States World Hea lth Organization pneumococcal serology reference laboratory and National 
Institutes of Health pneumococcal reference laboratories), is a multiplexed OPA assay 
capable of measuring [ADDRESS_1141882] a total of 16 serot ypes of pneumococci 
[Burton, Robert L . and Nahm, Moon H. 2006] . The OPA is an antibod y-mediated killing 
assay  that measures the ability of human serum to kill S. pneumoniae serot ypes with the help 
of complement and phagocytic effector ce lls. The ability  of the assay  to simultaneously  test 4 
seroty pes/run reduces the amount of serum needed for testing. The assay  readout is the 
opsonization index, which is the reciprocal of the highest dilution that gives ≥50% bacterial 
killing, as determin ed by [CONTACT_823572]. MSD has developed and 
optimized the MOPA in a high throughput micro -colony  platform. The MOPA assay  for all 
15 V114 serot ypes has undergone validation. The validation study evaluated various 
performance parame ters of the assay  including precision, relative accuracy/dilutional 
linearity , and specificity . The validation results were evaluated against pre -specified 
acceptance criteria for each of the parameters.
8.2.2 Electrochemiluminescence (ECL)
MSD has developed and optimized a multiplex, ECL -based detection method for the 
quantitation of IgG serotype -specific antibodies to the [ADDRESS_1141883]: V114 53
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
8.3 Safety Assessments
Details regarding specific safet y procedures/assessments to be performed in this study  are 
provided. The total amount of blood to be drawn over the course of the study (from prestu dy 
to poststudy  visits), including approximate blood volumes drawn b y visit and by [CONTACT_63533] t ype 
per participant, can be found in Section 8.
Planned time points for all safety assessments are provided in the SoA.
8.3.1 Physical Examinations
A complete ph ysical exa mination will be conducted by [CONTACT_63534] (consistent with local requirements) before vaccination at Visit 2 (Day  1).  A 
directed ph ysical examination will be conducted by [CONTACT_63534] (consistent with local requirements) before vaccination at Visit 4 (Week 8).
Investigators should pay  special attention to clinical signs related to previous illnesses.
8.3.[ADDRESS_1141884] cons istent with local requirements (sensitive to at least 25 IU beta human 
chorionic gonadotropin [β-hCG ]) must be performed before vaccination at Visit 2 (Day 1) 
and Visit 4 (Week 8) in WOCBP as described in Section 1.[ADDRESS_1141885] be negative before vaccination can occur.
8.3.3 HIV Serology, CD4+ T -cell count, and Plasma HIV RNA Testing
Serum for assessment of HIV serology and a blood sample for CD4+ T -cell count and 
plasma HIV RNA testing will be collected at Visit 1 (Screening) to confirm inclusion criteria 
related to HIV infection. Additionally  a blood sample for CD4+ T -cell count and plasma HIV 
RNA testing will be collected at Visit 3 (Day 30) and Visit 5 (Week 12).
8.3.4 Body Temperature Measurement 
Each participant's body  temperature must be taken before vaccination as described in 
Section 1.3.
Oral bod y temperatures will also be documented by [CONTACT_63535] -specified postvaccination follow -up period (Section 8.3.5).
For this study , any  oral or ty mpanic temperature ≥100.4°F (≥38.0°C), axillary or temporal
temperature ≥99.4°F (≥37.4°C), or rectal temperature ≥101.4°F (≥38.6°C) will be considered 
an AE of fever. All fevers must be reported Day  [ADDRESS_1141886]: V114 54
PROTOCOL/AMENDMENT N O.:018-[ADDRESS_1141887] be recorded on the appropriate eCRF.
Participants will use the eVRC (Section 8.1.9) to document the following informati on:
Oral bod y temperatures measured Day 1 (day of vaccination) through Day 5 
postvaccination;
Solicited injection -site AEs ( redness/ery thema, swelling, and tenderness/pain ) Day  1 
through Day  5 postvaccination;
Solicited sy stemic AEs ( muscle pain/my algia, j oint pain/arthralgia, headache, and 
tiredness/fatigue ) Day  1 through Day  14 postvaccination;
Any other injection -site or sy stemic AEs Day 1 through Day  14 postvaccination; and
Concomitant medications and nonstudy  vaccinations Day  1 to Day  14 postvaccinatio n
8.3.6 Clinical Laboratory Assessments
•Refer to Appendix [ADDRESS_1141888] of clinical laboratory tests to be performed and to the 
SoA for the timing and frequency .
•All protocol -required laboratory  assessments, as defined in Appendix [ADDRESS_1141889] ance with the laboratory  manual and the SoA .
•If laboratory  values from nonprotocol specified laboratory  assessments performed at 
the institution’s local laboratory  require a change in study  participant management or 
are considered clinically  significant b ythe investigator (eg, SAE or AE or dose 
modification), then the results must be recorded in the appropriate CRF (eg, SL AB).
•For an y laboratory  tests with values considered clinically  significantl y abnormal 
during participation in the study  or within [ADDRESS_1141890]: V114 55
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
8.4 Adverse Events (AEs), Seriou s Adverse Events (SAEs) ,and Other Reportable 
Safety Events
The definitions of an AE or SAE, as well as the method of recording, evaluating, and 
assessing causalit y of AE and SAE and the procedures for completing and transmitting AE, 
SAE, and other reportable safet y event reports can be found in Appendix 3.
Adverse events, SAEs, and other reportable safety events will be reported by  [CONTACT_2299] 
(or, w hen appropriate, b y a caregiver or surrogate).
The investigator and an y designees are responsible for de tecting, documenting, and reporting 
events that meet the definition of an AE or SAE, as well as other reportable safet y events. 
Investigators remain responsible for following up AE, SAEs, and other reportable safety 
events for outcome according to Section 8.4.3.
The investigator, who is a qualified ph ysician, will assess events that meet the definition of 
an AE or SAE as well as other reportable safet y events with respect to seriousness, 
intensity /toxicity  and causality .
8.4.1 Time Period and Frequency for Collecting AE, SAE ,and Other Reportable 
Safety Event Information
All AEs, SAEs, and other reportable safety events that occur after the consent form is signed 
but before allocation/randomization must be reported by  [CONTACT_63536] , or are the result of a protocol -specified 
intervention, including but not limited to washout or discontinuation of usual therap y, diet, 
placebo treatment, or a procedure.
All AEs, SAEs, and other reportable safety even ts must be reported b y the investigator from 
the day  of allocation/randomization to the first vaccination and from the day of each 
vaccination through [ADDRESS_1141891] also be reported throughout the 
duration of the individual’s particip ation in the study , regardless of whether or not related to 
the Sponsor’s product .
Additionally , any SAE brought to the attention of an investigator at an y time outside of the 
time period specified in the previous paragraph also must be reported immediatel y to the 
Sponsor if the event is either:
1.A death that occurs prior to the participant completing the study.
OR
2.An SAE that is considered by  [CONTACT_19427] a qualified ph ysician to be vaccine 
related.
Investigators are not obligated to activel y seek AE or SAE or other reportable safet y events 
in former stud y participants. However, if the investigator learns of an y SAE, including a  
  04Y2KD 
  05KG4L
PRODUCT: V114 56
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
death, at an y time after a participant has been discharged from the study, and he/she 
considers the event to be reasonabl y related to the study intervention or study  participation, 
the investigator must promptly  notify  the Sponsor.
All initial and follow -up AEs, SAEs, and other reportable safety  events will be recorded and 
reported to the Sponsor or designee within the time frames as indicated in Table 3.
Table 3 Reporting Time Periods and Time Frames for A dverse Events and Other 
Reportable Safet y Events
Type of Event Reporting Time 
Period:
Consent to 
Randomization/ 
AllocationReporting Time 
Period:
Randomization/ 
Allocation 
through Protocol -
Specified Follow -
up PeriodReporting Time Period:
After the Protocol 
Specified Follow -up 
PeriodTimefram e to 
Report Event 
and Follow -
up 
Information 
to 
SPONSOR:
Non-Serious Adverse 
Event (NSAE)Report if:
-due to protocol -
specified 
intervention
-causes exclusion
-participant is 
receiving placebo 
run-in or other 
run-in treatmentReport all Not required Per data entry 
guidelines
Serious Adverse Event 
(SAE)Report if:
-due to protocol -
specified 
intervention
-causes exclusion
-participant is 
receiving placebo 
run-in or other 
run-in treatmentReport all Report if:
-drug/vaccine related.
-any death until 
participant completion of 
study
(Follow  ongoing to 
outcome)Within 24 
hours of 
learning of 
event
Pregnancy/Lactation 
ExposureReport if:
-due to 
intervention
-causes exclusionReport all Previously reported –
Follow  to 
completion/termination; 
report outcomeWithin [ADDRESS_1141892] for this study Not 
applicable
Cancer Report if:
-due to 
intervention
-causes exclusionReport all Not required Within 5 
calendar days 
of learning of 
event
Overdose Report if:
-receiving 
placebo run -in or 
other run -in 
medication Report all Not required Within [ADDRESS_1141893]: V114 57
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
8.4.2 Method of Detecting AE s, SAE s,and Other Reportable Safety Events
Care will be taken not to introduce bias when detecting AE and/or SAE and other reportable 
safet y events. Open -ended and nonlea ding verbal questioning of the participant is the 
preferred method to inquire about AE occurrence.
8.4.3 Follow -up of AE, SAE ,and Other Reportable Safety Event Information
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subsequent visits/contacts. All AE, SAE, and other reportable safet y events 
including pregnancy  and exposure during breastfeeding, cancer, and overdose will be 
followed until resolution, stabilization, until the event is otherwise explained, or the 
participant is lost to follow -up (as defined in Section 7.3). In addition, the investigator will 
make every  attempt to follow all nonserious AEs that occur in randomized participants for 
outcome. Further information on follow -up procedures is given in Appendix 3 .
8.4.4 Regulatory Reporting Requirements for SAE
Prompt notification (within 24 hours) by  [CONTACT_63537] y of participants and the 
safety of a stud y intervention under clinical investigation are met.
The Sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory agencies about the safet y of a stud y intervention under clinical investigation. All 
AEs will be reported to regulatory  authorities, IRB/IECs, and investigators in accordance 
with all applicable global laws and regul ations (ie, per ICH Topic E6 (R2 ) Guidel ines for 
Good Clinical Practice [GCP] ).
Investigator safety  reports must be prepared for suspected unexpected serious adverse 
reactions (S[LOCATION_003]R s) according to local regulatory  requirements and Sponsor policy  and 
forwarded to investigators as necessary .
An investigator who receives an investigator safety report describing an SAE or other 
specific safet y information (eg, summary or listing of SAE) from the Sponsor will file it 
along with the IB and will notify  the IRB/IEC, if appropriate according to local req uirements .
8.4.5 Pregnancy and Exposure During Breastfeeding
Although pregnancy  and infant exposure during breastfeeding are not considered AEs, an y 
pregnancy  or infant exposure during breastfeeding in a participant (spontaneously reported to 
the investigator or their designee) that occurs during the stud y are reportable to the Sponsor.
All reported pregnancies must be followed to the completion/termination of the pregnancy . 
Pregnancy  outcomes of spontaneous abortion, missed abortion, benign h ydatidiform mole, 
blighted ovum, fetal death, intrauterine death, miscarriage, and stillbirth must be reported as 
serious events (Important Medical Events). If the pregnancy continues to term, the outcome 
(health of infant) must also be reported. 
  04Y2KD 
  05KG4L
PRODUCT: V114 58
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
8.4.6 Disease -related Events and/ or Disease -related Outcomes Not Qualifying as 
AEs or SAEs
This is not applicable to this study .
8.4.[ADDRESS_1141894] be reported b y the investigator within 5 calendar days to the 
Sponsor either b y electronic media or paper. Electronic reporting procedures can be found in 
the electronic data collection (EDC )data entry  guidelines. Paper reporting procedures can be 
found in the Investigator Trial File Binder (or equivalent).
8.6 Pharmacokinetics
Pharmacokinetic parameters will not be evaluated in this study .
8.7 Pharmacodynamics
Pharmacod ynamic parameters will not be evaluated in this study .
8.8 Future Biomedical Research Sample Collection
If the participant signs the future biomedical r esearch consent, the following specime ns will 
be obtained as part of future biomedical r esearch:
•DNA for future research
•Leftover stud y serum after completion of immunogenicity tes ting stored for future 
research
8.[ADDRESS_1141895]: V114 59
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
8.10 Biomarkers
Biomarkers are not evaluated in this study .
8.11 Medical Resource Utilization and Health Economics
Medical Resource Utilization and Health Economics are not evaluated in this study .
8.12 Visit Requirements
Visit requirements are outlined in Section 1.3. Specific procedure -related details are provided 
in Section 8.
8.12.1 Screening
Approximately  30days prior to treatment allocation/randomization, potential participants 
will be evaluated to determine that they  fulfill the entry  requirements as set forth in 
Section 5.1.Screening procedure s may  be repeated after consultation with the Sponsor.
8.12.2 Treatment Period/Vaccination Visit
Requirements during the treatment period are outlined in Section 1.3.
8.12.3 Discontinued Participants Continuing to be Monitored in the Study
In this trial, a participant may discontinue from study  treatment (ie, vaccination) but continue 
to participate in subsequent protocol visits as outlined in Section 1.3, as long as the 
participant does not withdraw consent.  Protocol -specified activities including AE monitoring 
should occur at these visits .
9 STATISTICAL ANALYSIS PLAN
This section outlines the statistical analysis strategy and procedures for the study.  Changes 
to analy ses made after the protocol has been finalized, but prior to unblinding, will be 
documented in a supplemental Statistical Analy sis Plan and referenced in the Clinical Study  
Report (CSR) for the study .  Post hoc exploratory anal yses will be clearl y identified in the 
CSR. 
  04Y2KD 
  05KG4L
PRODUCT: V114 60
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
9.1 Statistical Analysis Plan Summary
Key elements of the statistical anal ysis plan are summarized below; the comprehensive plan 
is provided in Sections 9.2 through 9.12.
Study Design Overview A Phase 3, Multicenter, Randomized, Double -Blind, Active Comparator -
Controlled Study to Evaluate the Safety, Tolerability, and 
Immunogenicity of V114 Follow ed by  [CONTACT_63491]™ 23 Eight Wee ks Later in Adults Infected with HIV
(PNEU –WAY)
Intervention Assignment Participants will be randomly assigned in a 1:1 ratio to V114 or 
Prevnar 13™ , respectively. Randomization will be stratified into 3 
groups based on the participant’s CD4+ T -cell count at screening ( ≥50 to 
<200, ≥200 to <500, and ≥500 )as described in Section 6.3.2.
Analysis Populations Immunogenicity : Per -Protocol (PP)
Safety : All Participants as Treated (APaT)
Prim ary Endpoint(s) Immunogenicity :
Serotype -specific OPA GMTs and IgG GMCs at 30 days 
postvaccination with V114 or Prevnar 13™ (Day 30 )
Safety : 
Proportion of participants with solicited injection -site AEs 
(redness /erythema , swelling, tenderness /pain) from Day 1 through 
Day 5 following V114 orPrevnar 13™ 
Proportion of participants with solicited systemic AEs (muscle 
pain/myalgia , joint pain /arthralgia , headache, and tiredness /fatigue)
from Day 1 through Day 14 follow ing V114 or Prevnar 13™
Proportion of participants with vaccine -related SAEs in the 8 w eeks 
following V114 orPrevnar 13™ (from Day 1 through Week 8)
Key Secondary Endpoints Immunogenicity :
Serotype -specific OPA GMTs and IgG GMCs at 30 days 
postvaccination with PNEUMOVAX ™23(Week 12)
Safety : 
Proportion of participants with solicited injection -site AEs 
(redness /erythema , swelling, tenderness /pain) from Day 1 through 
Day 5 following PNEUMOVAX ™23
Proportion of participants with solicited systemic AEs (muscle 
pain/myalgia , joint pain/arthralgia , headache, and tiredness /fatigue)
from Day 1 through Day 14 follow ing PNEUMOVAX ™23
Proportion of participants with vaccine -related SAEs in the 4 
months following PNEUMOVAX ™23(from Week 8 through 
Month 6)
Statistical Methods for Key 
Immunogenicity AnalysesImmunogenicity analyses will be conducted for each of the [ADDRESS_1141896] -vaccination with V114 or Prevnar 13™ (Day 30) w ill 
include descriptive summaries and w ithin-group 95% CIs to be calculated 
for each vaccination group. A similar statistical approach w ill be used to 
evaluate the OPA and IgG responses at Week 12. 
  04Y2KD 
  05KG4L
PRODUCT: V114 61
PROTOCOL/AMENDMENT N O.:018-[ADDRESS_1141897] safety parameters, 95% 
within -group CIswill be provided. 
Interim Analyses To support the periodic review of safety and tolerability data across the 
adult V114 Phase [ADDRESS_1141898] to 
enable a benefit -risk assessment.
Multiplicity No adjustment will be made for multiplicity.
Sample Size and Power Immunogenicity :
This study will randomize approximately 150 participants into the V114 
group and 150 participants into the Prevnar 13™ group.  It is assumed 
that approximately 135 participants per group will be evaluable for the 
PPi[INVESTIGATOR_823561] 30 (90% evaluability rate). There 
are no hypotheses to be evaluated, but Section 9.9.1 provides information 
about the expected variability of the OPA GMTs and IgG GMCs given
the sample size.  
Safety: 
Section 9.9.2 provides information about the ability of this study to 
estimate the incidence of AEs within the V114 group. 
9.2 Responsibility for Analyses/In -house Blinding
The statistical anal ysis of the data obtained from this study  will be the responsibility  of the 
Clinical Biostatistics department of the Sponsor.
This study  will be conducted as a double -blind study  under in -house blinding procedures. 
The official, final database will not be unblinded until medical/scientific review has been 
performed, protocol deviations have been identified, and data have been declared final and 
complete.
The Clinical Biostatistics department will generate the randomized allocation schedule(s) for 
study  intervention assignment. Randomization will be implemented in an IRT.
Blinding issues related to the planned interim analyses are described in Section 9.7.  
9.3 Hypotheses/Estimation
Objectives of the stud y are stated in Section 3. This is an estimation study  and no formal 
hypothesis testing will be performed.
9.[ADDRESS_1141899]: V114 62
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
9.4.1 Immunogenicity Endpoints
A description of immunogenicity  assessments is contained in Section 8.2.
Immune responses will be measured for each of the following serot ypes contained in V114: 
1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F .
The primary  immunogenicity  analy sis endpoints are the serot ype -specific OPA GMTs and 
IgG GMCs at 30days postvaccination with V114 or Prevn ar13™ (Day  30).
The secondary  immunogenicity  analysisendpoints are the serot ype-specific OPA GMTs and 
IgG GMCs at 30days postvaccination with PNEUMOVAX™23 (Week 12).
The exploratory  immunogenicity  analysis endpoints include:
Seroty pe-specific GMFRs and proportion sof participant s with a ≥4-fold rise from 
prevaccination (Day 1) to 30 day s postvaccination with V114 or Prevnar 13™ (Day  
30) for both OPA and IgG responses
Seroty pe-specific GMFRs and proportion sof participant s with a ≥4-fold rise from 
prevacc ination (Day 1) to 30 day s postvaccination with PNEUMOVAX™23 
(Week 12) for both OPA and IgG responses
9.4.2 Safety Endpoints
A description of safet y measures is contained in Sections 8.3 and 8.4. The anal ysis of safety  
results is described in Section 9.6.2.
Safety  and tolerability  will be assessed b y clinical review of all relevant parameters including 
adverse events and postvaccination temperature measurements following V114 or 
Prevnar 13™ and following PNEUMOVAX™23 (separately ). 
The safet y analysis endpoints include :
Proportion of participants with solicited injection -site AEs (redness /erythema , 
swelling, tenderness /pain ) from Day 1 through Day 5 postvaccination
Proportion of participants with solicited sy stemic AEs (muscle pain /myalgia, joint 
pain/arthralgia ,headache, and tiredness /fatigue ) from Day 1 through Day 14 
postvaccination 
Proportion sof participants with the broad AE categories consisting of an y AE, a 
vaccine -related AE, a SAE, an AE which is both vaccine -related and serious, and 
discontinuation due to an AE and the proportion of participants who died
Proportion of participants with maximum temperature measurements meeting the 
Brighton Collaboration cut points from Day [ADDRESS_1141900]: V114 63
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
9.5 Analysis Populations
9.5.1 Immunogenicity Analysis Popu lations
The Per -Protocol (PP) population will serve as the primary  population for the anal ysis of 
immunogenicit y data in this study. The PP population consists of all randomized participants 
without deviations from the protocol that may  substantially  affec t the results of the 
immunogenicit y endpoint(s). Potential d eviations that may  result in the exclusion of a 
participant from the PP population for all immunogenicity anal yses include:
Failure to receive an y study vaccine at Visit 2 (Day  1)
Failure to receive correct clinical material as per randomization schedule (ie, 
participants who were cross -treated) 
Receipt of prohibited medication or prohibited vac cine prior to stud y vaccination
Additional potential deviations that may  result in the exclusion of a participant from the PP 
population for specific immunogenicit y analyses (depending on the time point) include:
Failure to receive PNEUMOVAX™23
Receipt of prohibited medication or prohibited vaccine prior to a blood sample 
collection 
Collection of blood sample outside of the pre -specified window (as described in 
Section 1.3)
The final determination on protocol deviations, and thereb y the composition of the PP 
population, will be made prior to the final unblinding of the database. Participants will be 
included in the vaccination group to which they  are randomized for the analy sis of 
immunogenicit y data using the PP population.
A supportive anal ysis using the Full Anal ysis Set (FAS) population will also be performed 
for the primary  immunogenicity  endpoin ts. The FAS population consists of all randomized 
participants who received at least [ADDRESS_1141901] 1serology  result. 
Participants will be included in the vaccination group to which they are randomized for the 
analysis of immunogenicity  data using the FAS population. 
9.5.2 Safety Analysis Populations
Safety  anal yses will be conducted in the All Participants as Treated (APaT) population, 
which consists of all randomized participants who received at least [ADDRESS_1141902]: V114 64
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
vaccination; such participants will be included in the treatment group corresponding to the 
study  vaccination actually  received.
At least 1 temperature measurement obtained subsequent to study  intervention is required for 
inclusion in the analy ses of tempera ture.  
9.6 Statistical Methods
Statistical testing and inference for immunogenicity  and safet y anal yses are described in 
Section 9.6.1 and Section 9.6.2, respectivel y. Section 9.6.3 describes how demographic and 
baseline characteristics will be summarized.
9.6.1 Statistical Methods for Immunogenicity Analyses
This section describes the statistical methods that address the primary and secondary 
immunogenicit y objectives. Methods related to exploratory objectives will be further 
described in the supplemental Statistic al Analy sis Plan .
Immunogenicit y anal yses will be conducted for each of the 15 pneumococcal serot ypes in 
V114 separatel y. To address the primary  immunogenicity  objective, evaluation of the OPA 
GMTs and IgG GMCs at 30 day s postvaccination with V114 or Prevn ar13™ (Day  30) will 
include descriptive summaries and within -group 95% CI s to be calculated for each 
vaccination group.  Point estimates for the OPA GMTs and IgG GMCs will be calculated b y 
exponentiating the estimates of the mean of the natural log values . The within -group CIs will 
be derived b y exponentiating the CIs of the mean of the natural log values based on the t -
distribution.
A similar statistical approach will be used to evaluate the OPA and IgG responses at 30 days 
postvaccination with PNEUMOVAX™ 23 (Week 12). 
To address the exploratory immunogenicit y objective s aiming to evaluate the OPA GMT s
and the IgG GMCs 30 day s postvaccination with V114 or Prevnar 13™ (Day  30) and at 30 
days postvaccination with PNEUMOVAX™23 (Week 12) for participants admin istered 
V114 compared to participants admi nistered Prevnar 13™ , the seroty pe-specific OPA GMTs 
and IgG GMTs will be compared between vaccination groups through the estimation of 
seroty pe-specific OPA GMT ratios and IgG GMC ratios for each of the 15 serotyp es in V114
at each of these timepoints . Estimation of the OPA GMT ratios and IgG GMC ratios and 
computation of the corresponding 95% CIs will be calculated using a constrained 
longitudinal data analy sis(cLDA )method proposed by  [CONTACT_165381] [Liang, K -Y and 
Zeger, S. L. 2000] . Details regarding the cLDA models will be included in the supplemental 
Statistical Analy sis Plan .
Reverse Cumulative Distribution Curves for OPA titers and IgG concentrations will be 
graphicall y displayed b y seroty pe at each of the following time points: Day  [ADDRESS_1141903]: V114 65
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
Table 4 Analy sis Strategy  for Immunogenicit y Va riables
Endpoint/Variable
(Description, Time Point)Primary vs. 
Supportive 
Approach†Statistical 
MethodAnalysis 
PopulationMissing Data 
Approach
Prim ary Endpoints
OPA GMTs and IgG GMCs at Day  30P Descriptive 
Statistics
(estimate, 95%
CI)PP Missing data 
will not be 
imputed S FAS
Secondary Endpoints
OPA GMTs and IgG GMCs at Week 12P Descriptive 
Statistics
(estimate, 95%
CI)PP Missing data 
will not be 
imputed
†P=Primary approach; S=Supportive approach.
CI= confidence interval ; FAS =Full Analysis Set; GMC = Geom etric Mean Concentration; GMT = 
Geom etric Mean Titer; IgG =Immunoglobulin G; OPA = opsonophago cytic activity; PP =Per-Protocol .
9.6.2 Statistical Methods for Safety Analyses
Safety  and tolerability  will be assessed b y clinical review of all relevant parameters including 
AEs and postvaccination temperature measurements.
The anal ysis strategy  for safet y parameters following each vaccination is summarized in 
Table 5.  The proportion of participants with solicited injection -site AEs (redn ess/ery thema, 
swelling, tenderness/pain from Day  1 to Day  5 postvaccination) and solicited sy stemic AEs 
(muscle pain/my algia, joint pain/arthralgia, headache, and tiredness/fatigue from Day  1 to 
Day 14 postvaccination) will be provided along with the corre sponding within -group 95% 
CIs (based on the exact binomial method proposed by  [CONTACT_93325] [Clopper, C. J. 
and Pearson, E. S. 1934] ).  In addition, the broad AE categories consisting of the proportion 
of participants with an y AE, a vaccine -related AE, a SAE, an AE which is both vaccine -
related and serious, discontinuation due to an AE, and the proportion of participants who died 
will be summarized in the same manner.  The proportion of participants with ma ximum 
temperature measurements meeting the Brighton Collaboration cut points (from Day  1 
through Day  5) will also will be provided along with the corresponding within -group 95% 
CIs. Point estimates by  [CONTACT_823573] 
(specific AE terms and system organ class terms).
The anal ysis of safet y parameters will be evaluated at 2 separate time points:  (1) following 
administration of V114 or Prevnar 13™ and (2) following administration of 
PNEUMOVAX™23.  Descriptive summaries of AEs following administration of V114 or 
Prevnar 13™ will include non-serious adverse events (NSAEs) within 14 day s of vaccination 
and SAEs occurring Day  1 through Week 8 ( before vaccination with PNEUMOVAX™23). 
Descriptive summaries of AEs fol lowing administration of PNEUMOVAX™[ADDRESS_1141904]: V114 66
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
NSAEs within 14 day s of vaccination and SAEs occurring Week 8 (Day  1 relative to 
vaccination with PNEUMOVAX™23) through Month 6 (end of the study). 
Safety  anal yses will be based on the observed data (ie, with no imputation of missing data).
Table 5 Analy sis Strategy for Safety  Parameters Following Each Vaccination
Safety Endpoint95% CI for Within -Group 
ComparisonDescriptive Statistics
Injection -site redness/erythema (Days 1 to 5)†X X
Injection -site swelling (Days 1 to 5)†X X
Injection -site tenderness/pain (Days 1 to 5)†X X
Muscle pain/myalgia (Days 1 to 14)†X X
Joint pain/arthralgia (Days 1 to 14)†X X
Headache (Days 1 to 14)†X X
Tiredness/fatigue (Days 1 to 14)†X X
Any AE‡X X
Any vaccine -related AE‡X X
Any SAE‡X X
Any vaccine -related SAE‡X X
Discontinuation due to AE‡X X
Death‡X X
Maximum temperature measurements meeting the Brighton 
Collaboration cut points (Days 1 to 5)X X
Specific AEs by [CONTACT_766086] X
†Includes solicited events only.
‡These endpoints are broad adverse event categories. For example, descriptive statistics for the safety endpoint of “Any AE” 
will provide the number and percentage of participants with at least 1AE.
AE=adverse event; CI = confidence interval; PT=preferred term; SAE =serious adverse event; SOC =System Organ 
Class; X =results will be provided.
9.6.3 Demographic and Baseline Characteristics
The comparability  of the vaccination groups for each relevant demog raphic and baseline 
characteristic will be assessed by [CONTACT_93329]. No statistical hypothesis tests 
will be performed on these characteristics. The number and percentage of participants 
screened and randomized and the primary  reasons for scre ening failure and discontinuation 
will be display ed.  Demographic variables (eg, age, race, and gender), baseline 
characteristics, prior and concomitant vaccinations and therapi[INVESTIGATOR_823562].
9.[ADDRESS_1141905]: V114 67
PROTOCOL/AMENDMENT N O.:018-[ADDRESS_1141906] to enable a benefit -
risk assessment.
Study  enrollment is likely  to be ongoing at the time of any  interim analy ses. Blinding to 
intervention assignment will be maintained at all investigational sites. The results of interim 
analyses will not be shared with the investigators prior to the completion of the study. 
Participant -level unblinding will be restricted to an external unblinded statistician performing 
the interim anal ysis.
TheDMC will serve as the primary  reviewer of the results of the s afety interim anal yses and 
will make recommendations for discontinuation of the study or protocol modifications to an 
executive committee of the Sponsor (see Appendix 1 for details on the Committees Structure 
for this study ). If the DMC recommends modifications to the design of the protocol or 
discontinuation of the study , this executive committee (and potentiall y other limited Sponsor
personnel) may  be unblinded to results at the intervention level in order to act on these 
recommendations. The extent to wh ich individuals are unblinded with respect to results of 
interim analy ses will be documented by  [CONTACT_63539]. Additional logistical 
details will be provided in the DMC Charter. 
Intervention -level results from the safety  interim analy sis wil l be provided by  [CONTACT_63540]. Prior to final study  unblinding, the unblinded statistician will not be 
involved in any  discussions regarding modifications to the protocol, statistical methods, 
identification of protocol deviations , or data validation efforts after the interim analyses.
9.8 Multiplicity
No adjustment will be made for multiplicity .
9.9 Sample Size and Power Calculations
9.9.1 Sample Size and Power for Immunogenicity Analyses
This is a descriptive study. This study  will randomize approximately  150participants into 
the V114 group and 150participants into the Prevnar 13™ group . It is assumed that 
approximately  135 participants per vaccination group will be evaluable for PP
immunogenicit y anal yses at Day 30 (based on a 90% evaluabi lity rate).
The width of the within -group 95% CIs for the seroty pe-specific OPA GMTs and IgG GMCs 
depend on the sample size, variability of the natural log concentrations, and the magnitude of 
the OPA GMT and IgG GMC. I n Table 6, 95% CIs for various hypothetical Day  [ADDRESS_1141907]: V114 68
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
Table 6 Within -Group 95% CI s for Vary ing Hy pothetical OPA GMTs and IgG GMCs and 
Vary ing Standard Deviations with [ADDRESS_1141908] Deviation of 
Natural Log Titers †Serotype -specific OPA GMT†
500 1000 5000
1.5 (388, 644) (776, 1288) (3882 ,6439)
2 (357, 700) (713, 1401) (3568, 7006)
2.5 (328,762) (656, 1525) (3280, 7623)
Serotype -specific IgG GMC†
1 5 10
1.0 (0.84, 1.18) (4.22, 5.92) (8.45, 11.84)
1.5 (0.78, 1.29) (3.88, 6.44) (7.76, 12.88)
2.0 (0.71, 1.40) (3.57, 7.01) (7.14, 14.01)
†The estimates of the standard deviation and OPA GMT sand IgG GMC sarerepresentative of those observed 
in V114 -006.
CI=Confidence Interval; GMC = Geometric Mean Concentration; GMT = Geometric Mean Titer; IgG = 
Immunoglobulin G; OPA =Opsonophagocytic Activity .
9.9.[ADDRESS_1141909] 1 SAE in this study  depends on the 
number of participants vaccinated and the underlying percentage of pa rticipants with a SAE 
in the study  population. Calculations below assume that 100% of the randomized participants 
will be evaluable for safety  analy ses. There is an 80% chance of observing at least 1SAE 
among 150 participants in the V114 group if the unde rlying incidence of a SAE is 1.1% (1 of 
every  93 participants receiving the vaccine). There is a 50% chance of observing at least 1
SAE among 150 participants in the V114 group if the underl ying incidence of a SAE is 0.5% 
(1 of every  213 participants recei ving the vaccine). If no SAEs are observed among the 150 
participants in the V114 group, this stud y will provide 97.5% confidence that the underl ying 
percentage of participants with a SAE is <2.4% (1 in every  41 participants) in the V114 
group.  
9.10 Subgroup Analyses
Seroty pe-specific OPA GMTs and serot ype-specific IgG GMCs and their corresponding 
within -group 95% CI s at Day  30 will be calculated for each CD4+ T -cell count subgroup (ie, 
≥50 to <200, ≥200 to <500, and ≥500) within each vaccination group. The 95% CI  will only  
be calculated if there are more than 10 participants in each vaccination group for each 
subgroup. In addition, a summary  of AEs and a summary  of solicited AEs will be provided 
for each subgroup of CD4+ T -cell count (point estimates only ). 
  04Y2KD 
  05KG4L
PRODUCT: V114 69
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
9.11 Compliance (Medication Adherence)
Given that participants will receive just a single dose of V114 or Prevnar 13™ and a single 
dose of PNEUMOVAX™23, compliance will not be calculated.  However, the number and 
proportion of randomized participants receiving each vaccination will be summarized 
(Section 9.12).
9.12 Extent of Exposure
The extent of exposure will be summarized by  [CONTACT_63542] V114 or Prevnar 13™ and the number and proportion of 
randomized participan ts administered PNEUMOVAX™23. 
  04Y2KD 
  05KG4L
PRODUCT: V114 70
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
10 SUPPORTING DOCUMENTA TION AND OPERATIONAL
CONSIDERATIONS
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.[ADDRESS_1141910] for Clinical Trials
[COMPANY_006] Sharp and Dohme Corp., a subsidiary of [COMPANY_006] & Co., Inc. (MS D)
Code of Conduct for Interventional Clinical Trials
I. Introduction
A.Purpose
MSD, through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our 
products. As such, we are committed to designing, implementing, conducting, analyzing and reporting these trials 
in compliance with the highest ethical and scientific standards. Protection of participant s inclinical trials is the 
overriding concern in the design of clinical trials . In all cases, M SD clinical trials will be conducted in compliance 
with local and/or national regulations (eg, International Council for Harmonisation Good Clinical Practice [ICH -
GCP]) and in accordance with the ethical principles that have their origin in the Declaration of Hel sinki.
B.Scope
Highest ethical and scientific standards shall be endorsed for all clinical interventional investigations sponsored by 
[CONTACT_19481] (parties) employed for their execution (eg, contract research organizations, 
collaborative research efforts). This Code is not intended to apply to trials that are observational in nature, or 
which are retrospective. Further, this Code does not apply to investigator -initiated trials , which are not under the 
full control of M SD.
II.Scientific Issues
A.Trial Conduct
1.Trial Design
Except for pi[INVESTIGATOR_19354], clinical trial protocols will be hypothesis -driven to assess safety, 
efficacy, and/or pharmacokinetic or pharmacodynamic indices of M SD or comparator products. 
Alternatively, M SDmay conduct outcomes research trials, trials to assess or validate various endpoint 
measures, or trials to determine patient preferences, etc.
The design (ie, participant population, duration, statistical power) must be adequate to address the specific
purpose of the trial. P articipants must meet protocol entry criteria to be enrolled in the trial. 
2.Site Selection
MSD selects investigative sites based on medical expert[INVESTIGATOR_18700], access to appropriate participants, adequacy of 
facilities and staff, previous pe rformance in clinical trials, as well as budgetary considerations. Prior to trial 
initiation, sites are evaluated by M SD personnel to assess the ability to successfully conduct the trial.
3.Site Monitoring/Scientific Integrity
Investigative t rial sites ar e monitored to assess compliance with the trial protocol and general principles of 
Good Clinical Practice (GCP). MSD reviews clinical data for accuracy, completeness, and consistency. Data 
are verified versus source documentation according to standard oper ating procedures. Per M SD policies and 
procedures, if fraud, scientific/research misc onduct, or serious GCP -noncompliance is suspected, the issues  
  04Y2KD 
  05KG4L
PRODUCT: V114 71
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
areinvestigated. When necessary, the clinical site will be closed, the responsible regulatory authorities an d 
ethics review committees notified.
B. Publication and Authorship
Regardless of trial outcome, MSD commits to publish primary and secondary results of its registered trials of 
marketed products in which treatment is assigned, according to the prespecified plans for data analysis. To the 
extent scientifically appropriate, MSDseeks to publish the results of other analyses it conducts that are important 
to patients, physicians, and payers. Some early phase or pi[INVESTIGATOR_26346] -generating rather 
than hypothesis testing , in such cases, publication of results may not be appropriate since the trial may be 
underpowered and the analyses complicated by [CONTACT_19482].
MSD’s policy on authorship is consistent with the re commendations published by [CONTACT_126558] (ICMJE). In summary, authorship should reflect significant contribution to the design and 
conduct of the trial, performance or interpretation of the analysis, and/or writing of the manuscript. All named 
authors must be able to defend the trial results and conclusions. M SD funding of a trial will be acknowledged in 
publications.
III.Participant Protection
A. Ethics Committee Review (Institutiona Review Board [ IRB]/Independent Ethics Committee [ IEC])
All clinical trials will be reviewed and approved by [CONTACT_2717]/IEC before being initiated at each site. Significant 
changes or revisions to the protocol will be approved by [CONTACT_63543], except 
changes required urgently to protect participa nt safety that may be enacted in anticipation of ethics committee 
approval. For each site, the ethics committee and M SDwill approve the par ticipant informed consent form.
B. Safety
The guiding principle in decision -making in clinical trials is that partic ipant welfare is of primary importance. 
Potential participants will be informed of the risks and benefits of, as well as alternatives to, trial participation. At 
a minimum, trial designs will take into account the local stand ard of care.
All participation in M SD clinical trials is voluntary. Participants enter the trial only after informed consent is 
obtained. Participants may withdraw from a n MSD trial at any time, without any influence on their access to, or 
receipt of, medical care that may otherwise be available to them.
C. Confidentiality
MSD is committed to safeguarding participant confidentiality, to the greatest extent possible. Unless required by 
[CONTACT_2371], only the investigator, Sponsor (or representative), ethics committee, and/or regulatory authorities will have 
access to confidential medical records t hat might identify the participant by [CONTACT_2300].
D. Genomic Research
Genomic r esearch will only be conducted in accordance with a protocol and informed consent authorized by [CONTACT_63544] c ommittee.
IV. Financial C onsiderations
A. Paym ents to Investigators
Clinical trials are time -and labor -intensive. It is M SD’s policy to compensate investigators (or the sponsoring 
institution) in a fair manner for the work performed in support of M SD trials. M SD does not pay ince ntives to 
enroll participants in its trials. However, when enrollment is particularly challenging, additional payments may be 
made to compensate for the time spent in extra recruiting efforts. 
  04Y2KD 
  05KG4L
PRODUCT: V114 72
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
MSD does not pay for participant referrals. However, M SDmay co mpensate referring physicians for time spent 
on chart review to identify potentially eligible participants.
B.Clinical Research Funding
Informed consent forms will disclose that the trial is sponsored by M SDand that the investigator or sponsoring 
institu tion is being paid or provided a grant for performing the trial. However, the local ethics committee may 
wish to alter the wording of the disclosure statement to be consistent with financial practices at that institution. As 
noted above, all publications r esulting from M SD trials will indicate M SD as a source of funding.
C. Funding for Travel and Other Requests
Funding of travel by [CONTACT_19488] (eg, to scientific meetings, investigator meetings, etc.) will be 
consistent with local guideli nes and practices .
V. Investigator Commit ment
Investigators will be expected to review M SD’s Code of Conduct as an appendix to the trial protocol, and in signing the 
protocol, agree to support these ethical and scientific standards.
10.1.2 Financial Disclosure
Financial Disclosure requirements are outlined in the US Food and Drug Administration 
Regulations, Financial Disclosure b y Clinical I nvestigators (21 CFR Part 54). I t is the 
Sponsor's responsibility  to determine, based on these regulations, whether a reque st for 
Financial Disclosure information is required. It is the investigator's/subinvestigator's 
responsibility  to comply  with any  such request.
The investigator/subinvestigator(s) agree, if requested by  [CONTACT_19489] 21 
CFR Part 54, to pro vide his/her financial interests in and/or arrangements with the Sponsor to 
allow for the submission of complete and accurate certification and disclosure statements. 
The investigator/subinvestigator(s) further agree to provide this information on a 
Certif ication/Disclosure Form, commonly  known as a financial disclosure form, provided by  
[CONTACT_1034]. The investigator/subinvestigator(s) also consent to the transmission of this 
information to the Sponsor in the [LOCATION_002] for these purposes. This may invol ve the 
transmission of information to countries that do not have laws protecting personal data.
10.1.3 Data Protection
Participants will be assigned a unique identifier by [CONTACT_1034]. An y participant records or 
datasets that are transferred to the Sponsor will c ontain the identifier only; participant names 
or an y information that would make the participant identifiable will not be transferred.
The participant must be informed that his/her personal study -related data will be used by  [CONTACT_19490]. The level of disclosure must also be 
explained to the participant. 
The participant must be informed that his/her medical records may  be examined by  [CONTACT_555870], by  
[CONTACT_6667]/IEC members, and b y inspectors from regulatory authorities. 
  04Y2KD 
  05KG4L
PRODUCT: V114 73
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
[IP_ADDRESS] Confidentiality of Data
By [CONTACT_12570], the investigator affirms to the Sponsor that information furnished to 
the investigator b y the Sponsor will be maint ained in confidence, and such information will 
be divulged to the IRB, IEC,or similar or expert committee; affiliated institution and 
employ ees, only  under an appropriate understanding of confidentialit y with such board or 
committee, affiliated institutio n and employ ees. Data generated b y this study will be 
considered confidential by [CONTACT_093], except to the extent that it is included in a 
publication as provided in the Publications section of this protocol.
[IP_ADDRESS] Confidentiality of Participant Records
By[CONTACT_12570], the investigator agrees that the Sponsor (or Sponsor representative), 
IRB/IEC, or regulatory  authority  representatives may  consult and/or cop y study  documents to 
verify  worksheet/ CRF report form data. By  [CONTACT_17317], th e participant agrees 
to this process. If stud y documents will be photocopi[INVESTIGATOR_88648]/ CRF information, the participant will be identified b y unique code only; full 
names/initials will be masked prior to transmission to the Sponsor.
By [CONTACT_12570], the investigator agrees to treat all participant data used and 
disclosed in connection with this study  in accordance with all applicable privacy  laws, rules 
and regulations.
[IP_ADDRESS] Confidentiality of IRB/IEC Information
The Spon sor is required to record the name [CONTACT_19525]/IEC that reviews and 
approves this study . The Sponsor is also required to document that each IRB/IEC meets 
regulatory  and ICH GCP requirements b y requesting and maintaining records of the names 
andqualifications of the IRB/IEC members and to make these records available for 
regulatory  agency  review upon request b y those agencies.
10.1.4 Committees Structure
[IP_ADDRESS] Scientific Advisory Committee
This study  was developed in collaboration with a Scientific Advisory  Committee (SAC). The 
SAC is comprise d of both Sponsor and non -Sponsor scientific experts who provide input 
with respect to study  design, interpretation of study  results, and subsequent peer -reviewed 
scientific publications.
[IP_ADDRESS] Executive Oversight Committee
The Executive Oversight Committee (EOC) is comprise d  of members of Sponsor Senior 
Management. The EOC will receive and decide upon any  recommendations made by  [CONTACT_63547] . 
  04Y2KD 
  05KG4L
PRODUCT: V114 74
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
[IP_ADDRESS] External D ata Monitoring Committee
To supplement the routine study  monitoring outlined in this protocol, an external DMC will 
monitor the interim data from this study . The voting members of the committee are external 
to the Sponsor. The members of the DMC must not be involved with the study in an y other 
way (eg, th ey cannot be study  investigators) and must have no competing interests that could 
affect their roles with respect to the study .
The DMC will make recommendations to the EOC regarding steps to ensure both participant 
safet y and the continued ethical integri ty of the study . Also, the DMC will review interim 
study  results, consider the overall risk and benefit to study  participants (Section 9.7) and 
recommend to the EOC whether the stud y should continue in accordance with the protocol.
Specific details regardi ng composition, responsibilities, and governance, including the roles 
and responsibilities of the various members and the Sponsor protocol team ; meeting 
facilitation; the study  governance structure; and requirements for and proper documentation 
of DMC repo rts, minutes, and recommendations will be described in the DMC charter that is 
reviewed and approved by [CONTACT_63548].
10.1.[ADDRESS_1141911] (FDAAA) of 2007 
and the European Medicines Agency (EMA) clinical trial Directive 2001/20/EC, the Sponsor 
of the study  is solel y responsible for determining whether the stud yand its results a re subject
to the requirements for submission to http://www.clinicaltrials.gov, 
www.clinicaltrialsregister.eu or other local registries. MSD, as Sponsor of this study , will 
review this protocol and submit the information necessary  to fulfill these requirem ents. MSD 
entries are not limited to FDAAA or the EMA clinical trial directive mandated trials. 
Information posted will allow participants to identify  potentiall y appropriate studies for their 
disease conditions and pursue participation b y calling a centra l contact [CONTACT_126563]. 
  04Y2KD 
  05KG4L
PRODUCT: V114 75
PROTOCOL/AMENDMENT N O.:018-[ADDRESS_1141912] the study  in an efficient and 
diligent manner and in conformance with this protocol; generall y accepted standards of G CP
(eg, International Conference on Harmonization of Technical Requirements for Registration 
of Pharmaceuticals for Human Use G CP: Consolidated Guid eline and other generally  
accepted standards of good clinical practice); and all applicable federal, state and local laws, 
rules and regulations relating to the conduct of the clinical study. The Code of Conduct, a 
collection of goals and considerations th at govern the ethical and scientific conduct of 
clinical investigations sponsored b y MSD, is provided i n this appendix under the Code of 
Conduct for Clinical Studies.
The investigator agrees not to seek reimbursement from participants, their insurance 
providers, or from government programs for procedures included as part of the study 
reimbursed to the investigator b y the Sponsor.
The investigator will promptly  inform the Sponsor of an y regulatory authority inspection 
conducted for this study .
The investigat or agrees to provide the Sponsor with relevant information from inspection 
observations/findings to allow the Sponsor to assist in responding to an y citations resulting 
from regulatory  authority inspection and will provide the Sponsor with a copy  of the 
proposed response for consultation before submission to the regulatory  authority . 
Persons debarred from conducting or working on clinical studies by  [CONTACT_63550]’s studies. The inve stigator 
will immediately  disclose in writing to the Sponsor if any  person who is involved in 
conducting the study  is debarred or if any  proceeding for debarment is pending or, to the best 
of the investigator’s knowledge, threatened.
10.1.8 Data Quality Assurance
All participant data relating to the stud
y will be recorded on printed or electronic CRF unless 
transmitted to the Sponsor or designee electronically (eg, laboratory data). The investigator 
or qualified designee is responsible for verify ing that data entr ies are accurate and correct by  
[CONTACT_55896] y or electronically signing the CRF.
Detailed information regarding Data Management procedures for this protocol will be 
provided separatel y.
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF. 
  04Y2KD 
  05KG4L
PRODUCT: V114 76
PROTOCOL/AMENDMENT N O.:018-[ADDRESS_1141913] permit study -related monitoring, audits, IRB/IEC review, and 
regulatory  agency  inspections and provide direct access to source data documents.
Study  documentation will be promptly  and fully disclosed to the Sponsor by [CONTACT_63551], 
copy ing, review, and audit at reasonable times b y representatives of the Sponsor or an y 
regulatory  authorities. The i nvestigator agrees to promptly  take an y reasonable steps that are 
requested b y the Sponsor or any regulatory  authorit ies as a result of an audit or inspection to 
cure deficiencies in the stud y documentation and worksheets/CRFs .
The Sponsor or designee is responsible for the data management of this study including 
quality  checking of the data.
Study  monitors will perform ongoing source data review and verification to confirm that data 
entered into the CRF b y authorized site personnel are accurate, complete, and verifiable from 
source documents; that the safet y and rights of participants are being protected; and that the 
study  is being conducted in accordance with the currentl y approved protocol and an y other 
study  agreements, ICH GCP, and all applicable regu latory  requirements.
Records and documents, including signed ICF, pertaining to the conduct of this study  must 
be retained b y the investigator for 15 ye ars after study  completion unless local regulations or 
institutional policies require a longer retention period. No records may  be destroy ed during 
the retention period without the written approval of the Sponsor. No records may be 
transferred to another location or part y without written notification to the Sponsor.
10.1.9 Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected. Source documents are filed at the investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from source documents 
must be co nsistent with the source documents or the discrepancies must be explained. The 
investigator may  need to request previous medical records or transfer records, depending on 
the study . Also, current medical records must be available.
10.1.10 Study and Site Closure
The Sponsor or its designee may  stop the study  or study  site participation in the study  for 
medical, safety , regulatory , administrative, or other reasons consistent with applicable laws, 
regulations, and GCP.
In the event the Sponsor prematurel y terminates a particular study site, the Sponsor will 
promptly  notify  that study  site’s IRB/IEC. 
  04Y2KD 
  05KG4L
PRODUCT: V114 77
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
10.2 Appendix 2: Clinical Laboratory Tests
The tests detailed in Table 7will be performed according to local requirements. 
Protocol -specific requirements for inclusion or ex clusion of participants are detailed 
in Section 5 of the protocol.
Additional tests may  be performed at an y time during the study as determined 
necessary  by [CONTACT_63552] b y local regulations.
Table 7 Protocol -require d Safet yLaboratory  Assessments
Laboratory 
AssessmentsParameters
Other Screening 
TestsSerum or urine β-hCG pregnancy test (as needed for WOCBP)
Serum for HIV Serology
Blood sample for CD4+ T -cell count and plasma HIV RNA testing
β-hCG =β human chorionic gonadotropin ; HIV = human immunodeficiency virus; RNA = 
ribonucleic acid; WOCBP = woman/ women of childbearing potential . 
  04Y2KD 
  05KG4L
PRODUCT: V114 78
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.1 Definition of AE
AE definition
•An AE is an y untoward medical occurrence in a clinical study participant, temporally 
associated with the use of study  intervention, whether or not considered related to the 
study  intervention.
•NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a study intervention.
•NOTE: For purposes of AE definition, study  intervention (also referred to as 
Sponsor’s product) includes any  pharmaceutical product, biological product, vaccine, 
device, diagnostic agent, or protocol specified procedure whether investigational 
(including placebo or active comparator product) or marketed, manufactured by, 
licensed b y, provided b y, ordistributed by  [CONTACT_63553] .
Events meeting the AE definition
•Any abnormal laboratory test results (hematology , clinical chemistry, or urinaly sis) or 
other safet y assessments (eg, ECG, radiological scans, vital signs measurement s), 
including those that worsen from baseline, or are considered clinicall y significant in 
the medical and scientific judgment of the investigator.
•Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency  and/or intensity  of the condition.
•New conditions detected or diagnosed after stud y intervention administration even 
though it may  have been present before the start of the study .
•Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interacti on.
•Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication.
•For all reports of overdose (whether accidental or intentional) with an associated AE, 
the AE term should reflect the clinical s ymptoms or abnormal test result. An overdose 
without any  associated clinical sy mptoms or abnormal laboratory  results is reported 
using the terminology  “accidental or intentional overdose without adverse effect.”
•Any new cancer or progression of existing ca ncer. 
  04Y2KD 
  05KG4L
PRODUCT: V114 79
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
Events NOT meeting the AE d efinition
•Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that 
leads to the procedure is the AE.
•Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admissi on to a hospi[INVESTIGATOR_307]).
•Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
•Surgery  planned prior to informed consent to treat a pre -existing condition that has 
not wor sened.
•Refe r to Section 8.4.[ADDRESS_1141914] medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
•The term “ life-threatening ”in the definition of “serious ”refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event, which h ypothetically  might have caused death, if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_1081]
•Hospi[INVESTIGATOR_19357], regardless of length of stay, even 
if the hospi[INVESTIGATOR_2138] a precautionary  measure for continued observation. (Note: 
Hospi[INVESTIGATOR_19358] a pre -existing c ondition that has not 
worsened is not an SAE. A pre -existing condition is a clinical condition that is 
diagnosed prior to the use of an MSD product and is documented in the participant’s 
medical history .
d.Results in persistent or significant disability/inca pacity
•The term disability  means a substantial disruption of a person’s ability  to conduct 
normal life functions. 
  04Y2KD 
  05KG4L
PRODUCT: V114 80
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
•This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiti ng, diarrhea, influenza, 
and accidental trauma (eg, sprained ankle) that may interfere with or prevent 
every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
•In offspring of participant taking the produ ct regardless of time to diagnosis.
f.Other important medical events
•Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may 
not be immediately  life-threatening or result in death or hospi[INVESTIGATOR_63474] 1 
of the other outcomes listed in the above definition. These events should usually be 
considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency 
or drug a buse.
10.3.3 Additional Events Reported
Additional events that require r eporting
In addition to the above criteria, AEs meeting either of the below criteria, although not 
serious per ICH definition, are reportable to the Sponsor.
•Is a cancer
•Is associated with an overdose
10.3.4 Recording AE and SAE
AE and SAE r ecording
•When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory , and diagnostics reports) 
related to the event.
•The investigator will record all relevant AE/SAE information on the AE 
CRFs /worksheets at each examination. 
  04Y2KD 
  05KG4L
PRODUCT: V114 81
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
•It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to the Sponsor in lieu of completion of the AE CRF page.
•There may be instances when copi[INVESTIGATOR_19952] b y the Sponsor. I n this case, all participant identifiers, with the exception of 
the participant number, will be blinded on the copi[INVESTIGATOR_12997].
•The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. I n such cases, the diagnosis (not the 
individual signs/sy mptoms) will be documented as the AE/SAE.
Assessment of Intensity /Toxicity
•An event is defined as “serious ”when it meets at least 1 of the predefined outcomes 
as described in the definition of an SAE, not when it is rated as severe.
•The investigator will make an assessment of intensity  for each AE and SAE (and 
other reportable safet y event) reported during the study and assign it to 1 of the 
following categories:
-Mild: An event that is easily  tolerated b y the participant, causing minimal discomfort 
and not interfering with every day activities (for pediatri c studies, awareness of 
symptoms, but easily  tolerated).
-Moderate: An event that causes sufficient discomfort to interfere with normal 
every day activities (for pediatric studies definitel y acting like something is wrong).
-Severe: An event that prevents nor mal every day activities. An AE that is assessed as 
severe should not be confused with an SAE. Severe is a category  utilized for rating 
the intensity  of an event; and both AE and SAE can be assessed as severe (for 
pediatric studies, extremely distressed or unable to do usual activities).
•Injection -site redness /erythema or swelling from the day of vaccination through Day  
5 postvaccination will be evaluated b y maximum size.
•The investigator will make an assessment of toxicity for each AE and SAE (and other 
reportable event) reported during the stud y.  A toxicity  grade will be assigned to 
injection -site AEs, specific sy stemic AEs, other s ystemic AEs, and vital sign 
(temperature) AEs as shown in the following tables. The toxicity  grading scales used 
in this study are adapted from the “FDA Guidance for Industry : Toxicity  Grading 
Scale for Health y Adult and Adolescent Volunteers Enrolled in Preventive Vaccine 
Clinical Trials, September 2007.” 
  04Y2KD 
  05KG4L
PRODUCT: V114 82
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
Injection -site AE Toxicity Grading Scale
Injection -site Reaction 
to Study 
Vaccine/PlaceboaGrade 1 Grade 2 Grade 3 Grade 4
Injection -site AEs occurring Days 1 through 5 following receipt of study vaccine/placebo
Pain/Tenderness Does not interfere 
with activityRepeated use of non -
narcotic pain reliever 
>24 hours or 
interferes with 
activityAny use of narcotic 
pain reliever or 
prevents daily 
activityERvisit or 
hospi[INVESTIGATOR_2666]/Redness Size measured as
BSize measured as
C or DSize measured as
E→Necrosis or 
exfoliative dermatitis 
or results in ER visit 
or hospi[INVESTIGATOR_823563]/Swelling Size measured as 
BSize measured as
C or DSize measured as
E→Necrosis or ER visit 
or hospi[INVESTIGATOR_63478] -
narcotic pain reliever 
>24 hours or 
interferes with 
activityAny use of narcotic 
pain reliever or 
prevents daily 
activityER visit or 
hospi[INVESTIGATOR_63479] -site reaction that begins ≥ 6 days after receipt of study vaccine/placebo
Pain/tenderness
Erythema/Redness
Induration/Swelling
OtherDoes not interfere 
with activityRepeated use of non -
narcotic pain reliever 
>24 hours or 
interferes with 
activityAny use of narcotic 
pain reliever or 
prevents daily 
activityER visit or 
hospi[INVESTIGATOR_63480]:  AE = adverse event; ER = emergency room; eVRC = electro nic Vaccine Report Card; SAE = serious 
adverse event .
a Based upon information provided by [CONTACT_63554].  Erythema/Redness and 
Induration/Swelling are specific injection -site AEs with size designations of letters A through E →, based upon a graphic in 
the eVRC.  Size A is not assigned a toxicity grade; however, injection -site AEs that measure size A should be reported as 
adverse experiences.  If the participant has an ER visit or is hospi[INVESTIGATOR_63481] -site AE, that AE is to be assigned 
a toxicity grade of 4, regardless of the size measured.
Specific Systemic AE Toxicity Grading Scale
System ic (General)Mild 
(Grade 1)Moderate 
(Grade 2)Severe 
(Grade 3)Potentially Life 
Threatening
(Grade 4)
Headache No interference with 
activityRepeated use of non -
narcotic pain reliever 
>24hours or some 
interference with 
activitySignificant; any use of 
narcotic pain reliever 
or prevents daily 
activityER visit or 
hospi[INVESTIGATOR_63482]; prevents 
daily activityER visit or 
hospi[INVESTIGATOR_63483]; prevents 
daily activityER visit or 
hospi[INVESTIGATOR_63480]: AE = adverse event; ER = emergency room . 
  04Y2KD 
  05KG4L
PRODUCT: V114 83
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
Other Systemic AE Toxicity Grading Scale
System ic IllnessaMild 
(Grade 1)Moderate 
(Grade 2)Severe 
(Grade 3)Potentially Life 
Threatening
(Grade 4)b
Illness or clinical AE 
(as defined according 
to applicable 
regulations)No interference with 
activitySome interference with 
activity not requiring 
medical interventionPrevents daily activity 
and required medical 
interventionER visit or 
hospi[INVESTIGATOR_63480]: ER = emergency room; eVRC = electronic Vaccine Report Card; SAE = serious adverse event .
aBased upon information provided by [CONTACT_63555] -up period. For SAEs reported beyond the primary safety follow -up period, grading will be based upon the 
initial report and/or f ollow -up of the event.
bAEs resulting in death will be assessed as Grade 4
Vital Sign (Temperature) Toxicity Grading Scale
Vital SignsaMild 
(Grade 1)Moderate 
(Grade 2)Severe 
(Grade 3)Potentially Life 
Threatening
(Grade 4)
Fever (°C) b
(°F) b38.0 to 38.4
100.4 to 101.138.5 to 38.9
101.2 to 102.039.0 to 40.0
102.1 to 104.0>40.0
>104.[ADDRESS_1141915] for all vital sign requirements
b Oral temperature; no recent hot or cold beverages or smoking
Assessment of c ausality
•Did the Sponsor ’s product cause the AE?
•The determination of the likelihood that the Sponsor ’s product caused the AE will be 
provided b y an investigator who is a qualified physician. The investigator’s signed/dated 
initials on the source document or worksheet that supports the causalit y noted on the AE 
form, ensures that a medically  qualified assessment of causalit y was done. This initia lled 
document must be retained for the required regulatory time frame. The criteria below are 
intended as reference guidelines to assist the investigator in assessing the likelihood of a 
relationship between the test product and the AE based upon the available information.
•The following components are to be used to assess the relationship between the 
Sponsor ’s product and the AE; the greater the correlation with the components and 
their respective elements (in number and/or intensity ), the more likel y the Sponsor ’s 
product caused the AE:
-Exposure: Is there evidence that the participant was actuall y exposed to the 
Sponsor ’s product such as: reliable history , acceptable compliance assessment (diary , 
etc.), seroconversion or identification of vaccine virus in bodily  specimen? 
  04Y2KD 
  05KG4L
PRODUCT: V114 84
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
-Time Course: Did the AE follow in a reasonable temporal sequence from 
administration of the Sponsor ’s product? Is the time of onset of the AE compatible 
with a vaccine -induced effect?
-Likely Cause: Is the AE not reasonabl y explained by  [CONTACT_63556], other drug(s)/vaccine(s), or other host or environmental factors ?
-Rechallenge: Was th e participant re -exposed to the Sponsor ’s product in the study ?
-If yes, did the AE recur or worsen?
-If yes, this is a positive rechallenge.
-If no, this is a negative rechallenge.
(Note: This criterion is not applicable if: (1) the initial AE resulted in de ath or permanent 
disability , or (2) the study  is a single -dose vaccine study ); or (3) Sponsor ’s product(s) is/are 
used only  1 time.)
NOTE: IF A RECHALLENGE IS PL ANNED FOR AN AE THAT WAS SERI OUS AND 
MAY HAVE BEEN CAUSED BY [CONTACT_26370] ’S PRODUCT, OR I F RE -EXPOSURE 
TO THE SPONSOR ’S PRODUCT POSES ADDITIONAL POTENTIAL SI GNIFICANT 
RISK TO THE PARTI CIPANT THEN THE RECHALLENGE MUST BE APPROVED I N 
ADVANCE BY [CONTACT_63557], AND IF REQUI RED, THE 
IRB/IEC .
-Consistency with study intervention profile: Is the clinical/pathological 
presentation of the AE consistent with previous knowledge regarding the Sponsor ’s 
product or drug class pharmacology  or toxicology?
-The assessment of relationship will be reported on the CRFs /worksheets by [CONTACT_26368] a qualified phy sician according to his/her best clinical judgment, 
including consideration of the above elements.
-Use the following scale of criteria as guidance (not all criteria must be present to be 
indicative of a Sponsor ’s product relationship).
-Yes, there is a reasonable possibility  of Sponsor ’s product relationship:
-There is evidence of exposure to the Sponsor ’s product. The temporal sequence of the 
AE onset relative to the administration of the Sponsor ’s product is reasonable. The 
AE is more likely  explained by [CONTACT_1034] ’s product than by  [CONTACT_5748].
-No, there is not a reasonable possibility  of Sponsor ’s product relationship: 
  04Y2KD 
  05KG4L
PRODUCT: V114 85
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
-Participant did not receive the Sponsor ’s product OR temporal sequence of the AE 
onset relative to administration of the Sponsor ’s product is not reasonable OR the AE 
is more likely  explained by  [CONTACT_26372]’s product. (Also entered 
for a participant with overdose without an associated AE.)
•For each AE/SAE, the investigator must document in the medical note s that he/she has 
reviewed the AE/SAE and has provided an assessment of causalit y.
•There may  be situations in which an SAE has occurred and the investigator has minimal 
information to include in the initial report to the Sponsor. However, it is very important 
that the investigator always make an assessment of causalit y for every event before the 
initial transmission of the SAE data to the Sponsor.
•The investigator may change his/her opi[INVESTIGATOR_19954] -up 
information and send an SA E follow -up report with the updated causality  assessment.
•The causality  assessment is 1 of the criteria used when determining regulatory  reporting 
requirements.
Follow -up of AE and SAE
•The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested b y Sponsor 
to elucidate the nature and/or causalit y of the AE or SAE as fully as possible. This 
may include additional laboratory  tests or investigations, histopathological
examinations, or consultation with other health care professionals.
•New or updated information will be recorded in the CRF.
•The investigator will submit any  updated SAE data to the Sponsor within 24 hours of 
receipt of the information.
10.3.5 Reporting of AE, SAE, and Other Reportable Safety Events to the Sponsor
AE, SAE, and other reportable safety event reporting to Sponsor via electronic data 
collection tool
•The primary  mechanism for reporting to the Sponsor will be the electronic data 
collection (EDC) tool .
•Electronic reporting procedures can be found in the EDC data entry guidelines (or 
equivalent). 
  04Y2KD 
  05KG4L
PRODUCT: V114 86
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
•If the electronic s ystem is unavailable for more than 24 hours, then the site will use 
the paper AE Reporting form.
•Reference Section 8.4.1  for reporting ti me requirements.
•The site will enter the SAE data into the electronic sy stem as soon as it becomes 
available.
•After the stud y is completed at a given site, the EDC tool will be taken off -line to 
prevent the entry  of new data or changes to existing data.
•Ifa site receives a report of a new SAE from a study  participant or receives updated 
data on a previously  reported SAE after the EDC tool has been taken off -line, then the 
site can report this information on a paper SAE form or by [CONTACT_756] (see next 
sectio n).
•Contacts for SAE reporting can be found in the Investigator Stud y File Binder (or 
equivalent).
SAE reporting to the Sponsor via paper CRF
•If the EDC tool is not operational, facsimile transmission or secure e -mail of the SAE 
paper CRF is the preferred method to transmit this information to the Sponsor.
•In rare circumstances and in the absence of facsimile equipment, notification by  
[CONTACT_9337] a cop y of the SAE data collection tool sent by [CONTACT_19515].
•Initial noti fication via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
•Contacts and instructions for SAE reporting and paper reporting procedures can be 
found in the Investi gator Study  File Binder (or equivalent). 
  04Y2KD 
  05KG4L
PRODUCT: V114 87
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
10.4 Appendix 4: Medical Device Incidents: Definition and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
Not applicable. 
  04Y2KD 
  05KG4L
PRODUCT: V114 88
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
10.5 Appendix 5: Contraceptive Guidance and Pregnancy Testing
10.5.1 Definitions
Wome n of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile.
Women in the following categories are not considered WOCBP:
•Premenarchal
•Premenopausal female with 1 of the follow ing:
- Documented h ysterectomy
-Documented bilateral salpi[INVESTIGATOR_1656]
-Documented bilateral oophorectom y
Note: Documentation can come from the site personnel’s review of the participant’s medical 
records, medical examination, or medical history  interview.
•Postmen opausal female
-A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause .
•A high follicle -stimulating hormone (FSH) level in the postmenopausal range may  be 
used to confirm a postmenopausal state in women not using h ormonal contraception 
or hormone replacement therap y (HRT). However, in the absence of [ADDRESS_1141916]: V114 89
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
10.5.2 Contraception Requi rements
Female Participants
Female participants of childbearing potential are eligible to participate if they agree to use 
1of the contraception methods described in Table 8consistently  and correctly  during the 
protocol -defined time frame in Section 5.1.
Table 8 Contraceptive Methods
Acceptable Contraceptive Methods
Failure rate of >1% per year when used consistently and correctly.
●Male or female condom with or without spermicide
●Cervical cap, diaphragm or sponge with spermicide
Highly Effective Contraceptive Methods That Are User Dependenta
Failure rate of <1% per year when used consistently and correctly.
●Com bined (estrogen -and progestogen -containing) hormonal contraceptionb
○Oral
○Intravaginal
○Transdermal
○Injectable
●Progestogen only hormonal contraceptionb
○Oral
○Injectable
Highly Effective Methods That Have Low User Dependency
Failure rate of <1% per year when used consistently and correctly.
●Progestogen -only contraceptive implantb,c 
●Intrauterine hormone -releasing system (IUS)b
●Intrauterine device (IUD)
●Bilateral tubal occlusion
●Vasectomized partner
A vasectomized partner is a highly effective contraception method provided that the partner is the sole 
male sexual partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional 
highly effective method of contraception should be used.
●Sexual abstinence
Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study intervention. The 
reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the 
preferred and usual lifestyle of the participant.
Notes:
Use should be consistent with local regulations regarding the use of contraceptive methods for participants 
of clinical studies.
aTypi[INVESTIGATOR_63485] -use failure rates (ie, when used consistently and 
correctly).
bIf locally required , in accordance with Clinical Trial Facilitation Group (CTFG) guidelines, acceptable 
hormonal contraceptives are limited to those which inhibit ovulation. 
  04Y2KD 
  05KG4L
PRODUCT: V114 90
PROTOCOL/AMENDMENT N O.:018-[ADDRESS_1141917]: V114 91
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
10.6 Appendix 6: Collection and Management of Specimens for Future Biomedical 
Research
1.Definitions
Biomarker: A biologi cal molecule found in blood, other bod y fluids, or tissues that is
a sign of a normal or abnormal process or of a condition or disease. A biomarker may
be used to see how well the body responds to a treatment for a disease or condition . 
Pharmacogenomics: The investigation of variations of DNA and RNA characteristics 
as related to drug/vaccine response.2
Pharmacogenetics: A subset of pharmacogenomics, pharmacogenetics is the influence 
of variations in DNA sequence on drug/vaccine response.2
DNA: Deox yribonu cleic acid.
RNA: Ribonucleic acid.
2.Scope of Future Biomedical Research
The specimens consented and/or collected in this study  as outlined in Section 8. 8will be 
used in various experiments to understand:
The biology  of how drugs/vaccines work
Biomarkers responsible for how a drug/vaccine enters and is removed by [CONTACT_10489]
Other pathway s drugs/vaccines may  interact with
The biology  of disease
The specimen(s) may  be used for future assay  development and/or drug/vaccine 
development.
It is now well recognized that information obtained from studying and testing clinical 
specimens offers unique opportunities to enhance our understanding of how individuals 
respond to drugs/vaccines, enhance our understanding of human disease and ultimately  
improve public health th rough development of novel treatments targeted to populations 
with the greatest need. All specimens will be used by [CONTACT_63558]. 
  04Y2KD 
  05KG4L
PRODUCT: V114 92
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
3.Summary of Procedures for Future Biomedical Research .
1.Participants for Enrollment
All participants enrolled in the clinical study will be considered for enrollment in the 
future biomedical research substudy
2.Informed Consent
Informed consent for specimens (ie, DNA, RNA, protein, etc.) will be obtained 
during screening for protocol enroll ment from all participants or legal guardians, at a 
study  visit by  [CONTACT_63559] d esignate. Informed consent for future 
biomedical r esearch should be presented to the participants on the visit designated in 
the SoA. If delay ed, present con sent at next possible Participant Visit. Consent forms 
signed b y the participant will be kept at the clinical study site under secure storage for 
regulatory  reasons.
A template of each stud y site’s approved informed consent will be stored in the 
Sponsor’s clinical document repository .
3.eCRF Documentation for Future Biomedical Research Specimens
Documentat ion of participant consent for future biomedical research will be captured 
in the eCRFs . Any specimens for which such an informed consent cannot be verified
will be destroy ed.
4.Future Biomedical Research Specimen(s)
Collection of specimens for future biomedical r esearch will be performed as outlined 
in the SoA. I n general, if additional blood specimens are being collected for future 
biomedical r esearch, these will usually  be obtained at a time when the participant is 
having blood drawn for other study  purposes.
4.Confidential Participant Information for Future Biomedical Research
In order to optimize the resea rch that can be conducted with future biomedical r esearch 
specimens, it is critical to link participant' clinical information with future test results. I n 
fact little or no research can be conducted without connecting the clinical study data to 
the specimen. The clinical data allow specific analyses to be con ducted. Knowing 
participant characteristics like gender, age, medical history and treatment outcomes are 
critical to understanding clinical context of anal ytical results.
To maintain privacy  of information collect ed from specimens obtained for future 
biomedical r esearch, the Sponsor has developed secure policies and procedures. All 
specimens will be single -coded per ICH E15 guidelines as described below. 
  04Y2KD 
  05KG4L
PRODUCT: V114 93
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
At the clinical study  site, unique codes will be placed on the future biomedical r esearch 
specimens. This code is a random number which does not contain an y personally 
identify ing information embedded within it. The link (or key ) between participant 
identifiers and this unique code will be held at the study  site. No personal identifiers will 
appear on the specimen tube.
5.Biorepository Specimen Usage
Specimens obtained for the Sponsor will be used for anal yses using good scientific 
practices. Anal yses utilizing the future biomedical r esearch specimens may  be performed 
by [CONTACT_1034], or an additional third p arty (eg, a university  investigator) designated by 
[CONTACT_1034]. The investigator conducting the anal ysis will follow the Sponsor’s privacy 
and confidentialit y requirements. An y contracted third part y anal yses will conform to the 
specific scope o f anal ysis outlined in this substudy . Future biomedical r esearch 
specimens remaining with the third part y after specific anal ysis is performed will be 
reported to the Sponsor.
6.Withdrawal From Future Biomedical Research
Participants may withdraw their consent for futu re biomedical r esearch and ask that thei r 
biospecimens not be used for future biomedical r esearch. Participants may withdraw 
consent at an y time b y contact[CONTACT_154478] [INVESTIGATOR_63472]. If medical 
records for the main study are still av ailable, the investigator will contact [CONTACT_90095] ([EMAIL_1250]). 
Subsequently , the participant's specimens will be flagged in the biorepository  and 
restricted to main stud y use only . If specimens wer e collected from study participants 
specificall y for future biomedical r esearch, these specimens will be removed from the 
biorepository  and destroyed. Documentation will be sent to the investigator confirming 
withdrawal and/or destruction, if applicable. I t is the responsibility  of the investigator to 
inform the participant of completion of the withdrawal and/or destruction, if applicable. 
Any anal yses in progress at the time of request for withdrawal/destruction or alread y 
performed prior to the request be ing received b y the Sponsor will continue to be used as 
part of the overall research study  data and results. No new analy ses would be generated 
after the request is received.
In the event that the medical records for the main study  are no longer available (eg, if the 
investigator is no longer required b y regulatory authorities to retain the main study 
records) or the specimens have been completel y anonymized, there will no longer be a 
link between the participant’s personal information and their specimens. In this situation, 
the request for withdrawal of consent and/or destruction cannot be processed.
7.Retention of Specimens
Future biomedical r esearch specimens will be stored in the biorepository  for potential 
analysis for up to [ADDRESS_1141918]: V114 94
PROTOCOL/AMENDMENT N O.:018-[ADDRESS_1141919] results are accessible only to the 
authorized Sponsor representatives and the designated study administrator research 
personnel and/or collaborators. Database user au thentication is highl y secure, and is 
accomplished using network securit y policies and practices based on international 
standards to protect against unauthorized access.
9.Reporting of Future Biomedical Research Data to Participants
No information obtained f rom exploratory  laboratory  studies will be reported to the 
participant, famil y, or physicians. Principle reasons not to inform or return results to the 
participant include: Lack of relevance to participant health, limitations of predictive 
capability , and concerns regarding misinterpretation.
If important research findings are discovered, the Sponsor may publish results, present 
results in national meetings, and make results accessible on a public website in order to 
rapi[INVESTIGATOR_823564]. Participants will not be 
identified by  [CONTACT_63561].
10. Future Biomedical Research Study Population
Every  effort will be made to recruit all participants diagnosed and treated o n Sponsor 
clinical studies for f uture biomedical r esearch.
11.Risks Versus Benefits of Future Biomedical Research
For future biomedical research, risks to the participant have been minimized and are 
described in the Future Biomedical Research informed consent.
The Sponsor has developed strict security, policies, and procedures to address participant 
data privacy  concerns. Data privacy  risks are largely  limited to rare situations involving 
possible breach of confidentiality . In this highl y unlikely  situation, there is risk that the 
information, like all medical information, may  be misused. 
  04Y2KD 
  05KG4L
PRODUCT: V114 95
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
12.Questions
Any questions related to the future biomedical research should be e mailed directly  to 
[EMAIL_1250].
13.References
1.National Cancer Institute [Internet]: Available from 
https://www.cancer.gov/publications/dictionaries/cancer -terms?cdrid=[ZIP_CODE]
2.International Conference on Harmoni sation [Internet] : E15 : Definitions for Genomic 
Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample 
Coding Categories. Available from 
http://www.ich.org/products/guidelines/efficacy /efficacy -single/article/definitions -
for-genomic -biomarkers -pharmacogenomics -pharmacogenetics -genomic -data-and-
sample -cod.html 
3.Industry  Pharmacogenomics Working Group [Internet]: Understanding the I ntent, 
Scope and Public Health Benefits of Exploratory  Biomarker Research: A Guide for 
IRBs/IECs and Investigational Site Staff. Avail able at http://i -pwg.org/ 
4.Industry  Pharmacogenomics Working Group [Internet]: Pharmacogenomics 
Informational Brochure for I RBs/IECs and Investigational Site Staff. Available at 
http://i -pwg.org/ 
  04Y2KD 
  05KG4L
PRODUCT: V114 96
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
10.7 Appendix 7: Country -specific Requirements
Not applicable. 
  04Y2KD 
  05KG4L
PRODUCT: V114 97
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
10.8 Appendix 8: Abbreviations
Abbreviation Expanded Term
ACIP Advisory Committee on Immunization Practices
AE adverse event
APaT All Participants as Treated
ART antiretroviral therapy
β-hCG beta-human chorionic gonadotropin
CAPi[INVESTIGATOR_63487] -Acquired Pneumonia Immunization Trial in Adults
CI confidence interval
cLDA constrained Longitudinal Data Analysis
CRM [ADDRESS_1141920]
FSH follicle -stimulating hormone
GCP Good Clinical Practice
GMC Geom etric Mean Concentration
GMFR Geom etric Mean Fold Rise
GMT Geom etric Mean Titer
HIV Human Immunodeficiency Virus
HRT hormonal replacement therapy 
IB Investigator’s Brochure
ICF Informed Consent Form
ICH International Council for Harmonisation Good Clinical Practice
IgG Immunoglobulin G
IMP investigational medicinal product
IRB Institutional Review Board
IPD Invasive Pneumococcal Disease
IRT interactive response technology
IUD intrauterine device
IUS intrauterine hormone -releasing system
MOPA Multiplexed Opsonophagocytic Assay
MSD [COMPANY_006] Sharp & Dohme Corp.
NIMP non-investigational medicinal product
NSAE nonserious adverse event
OPA opsonophagocytic activity
PCV pneumococcal conjugate vaccine
PCV13 Prevnar 13™
PnECL pneumococcal electrochemiluminescence
PP Per-Protocol
PT preferred term
PPV23 PNEUMOVAX™[ADDRESS_1141921]: V114 98
PROTOCOL/AMENDMENT N O.:018-[ADDRESS_1141922]
SoA schedule of activities
SOC system o rgan class
sSAP supplemental statistical analysis plan
WHO World Health Organization
WOCBP woman/womenof childbearing potential 
  04Y2KD 
  05KG4L
PRODUCT: V114 99
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
11 REFERENCES
[Anttila, M., et al 
1999]Anttila M, Voutilainen M, Jäntti V, Eskola J, Käyht y H. 
Contribution of seroty pe-specific IgG concentration, IgG 
subclasses and relative antibody  avidity  to 
opsonophagocy tic activity  against Streptococcus 
pneumoniae. Clin Exp Immunol 1999;118(3):402 -7.03QY70
[Bhorat, A. E., et 
al2015]Bhorat AE, Madhi SA, Laudat F, Sundarai yer V, Gurtman 
A, Jansen KU, et al. Immunogenicity  and safety  of the 13 -
valent pneumococcal conjugate vaccine in HIV -infected 
individuals naive to pneumococcal vaccination. AIDS. 2015 
Jul 17;29(11):1345 -54.04NRV9
[Bonten, M. J., et 
al 2015]Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson 
S, Gault S, et al. Poly saccharide conjugate vaccine against 
pneumococcal pneumonia in adults. N Engl J Med. 2015 
Mar 19;372(12):1114 -25.04NFHD
[Burton, Robert L . 
andNahm, Moon 
H. 2006]Burton RL, Nahm MH. Development and validation of a 
fourfold multiplexed opsonization assay  (MOPA4) for 
pneumococcal antibodies. Clin Vaccine Immunol 
2006;13(9):1004 -9.03QT2R
[Castiglia P. 2014] Castiglia P. Recommendations for pneum ococcal 
immunization outside routine childhood immunization 
programs in Western Europe. Adv Ther. 
2014Oct;31(10):1011 -44.04P7L W
[Centers for 
Disease Control 
and Prevention 
(CDC) 2012]Centers for Disease Control and Prevention (CDC). Use of 
13-valent pne umococcal conjugate vaccine and 23 -valent 
pneumococcal poly saccharide vaccine for adults with 
immunocompromising conditions: recommendations of the 
Advisory  Committee on Immunization Practices (ACI P). 
MMWR Morb Mortal Wkly  Rep. [ADDRESS_1141923] 12;61(40):816 -
9.04NRTJ
[Centers for 
Disease Control 
and Prevention 
2008]Centers for Disease Control and Prevention (CDC). 
Invasive pneumococcal disease in children 5 years after 
conjugate vaccine introduction -eight states,1998 -2005. 
MMWR Morb Mortal Wkly  Rep. 2008 Feb 15; 57(6):144 -8.04KW8S
[Centers for 
Disease Control 
and Prevention 
2010]Centers for Disease Control and Prevention. Updated 
recommendations for prevention of invasive pneumococcal 
disease among adults using the 23 -valent pneumococcal 
polysaccharide vaccine (PPSV23). MMWR 
2010;59(34):[ADDRESS_1141924]: V114 100
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
[Centers for 
Disease Control 
and Prevention 
2010]Centers for Disease Control and Prevention. Prevention of 
Pneumococcal Disease Among Infants and Children -Use 
of 13- Valent Pneumococcal Conjugate Vaccine and 23-
Valent Pneumococcal Poly saccharide Vaccine; 
Recommendations of the Advisory  Committee on 
Immunization Practices (ACI P). MMWR 2010;59(RR -
11):1 -19.03RSB6
[Clopper, C. J. and 
Pearson, E. S. 
1934]Clopper CJ, Pearson ES. The use of confidence or fiducial 
limits illustrated in the case of the binomial. Biometrika 
1934;26(4):404 -13.03Q0L W
[European Centre 
for Disease 
Prevention and 
Control 2016]European Centre for Disease Prevention and Control. 
Annual Epi[INVESTIGATOR_63488] 2016 –Invasive 
pneumococcal d isease. [Internet]. Stockholm: ECDC; 2016. 
Available from: 
http://ecdc.europa.eu/en/healthtopi[INVESTIGATOR_1102]/pneumococcal_infecti
on/Pages/Annual -epi[INVESTIGATOR_904] -report -2016.aspx.04LP3M
[Farrell, D. J, et al 
2007]Farrell DJ, Klugman KP, Pi[INVESTIGATOR_63489] M. Increased 
antim icrobial resistance among nonvaccine serot ypes of 
Streptococcus pneumoniae in the pediatric population after 
the introduction of [ADDRESS_1141925] Dis J. 2007 Feb;26(2):123 -8.04KWD9
[Guevara, M., et al 
2016]Guevara M, Barricarte A, Torroba L, Herranz M, Gil -Setas 
A, Gil F, et al. Direct, indirect and total effects of 13 -valent 
pneumococcal conjugate vaccination on invasive 
pneumococcal disease in children in Navarra, Spain, 2001 
to 2014: cohort and case -control study . Euro Surveill. 
2016;21(14).04KSQ3
[Jokinen, J., et al 
2015]Jokinen J, Rinta -Kokko H, Siira L , Palmu AA, Virtanen MJ, 
Nohy nek H, et al. I mpact of ten -valent pneumococcal 
conjugate vaccination on invasive pneumococcal disease in 
Finnish children a population -based study . PLoS One. 2015 
Mar 17;10(3):e0120290.04KW7F
[Kobay ashi, M., et 
al 2015]Kobay ashi M, Bennett NM, Gierke R, Almendares O, 
Moore MR, Whitney  CG, et al. Intervals Between PCV13 
and PPSV23 Vaccines: Recommendations of the A dvisory  
Committee on I mmunization Practices (ACIP). MMWR 
Morb Mortal Wkly  Rep. 2015 Sep 4;64(34):944 -7.04P7L H
[Lepoutre, A., et al 
2015]Lepoutre A, Varon E, Georges S, Dorleans F, Janoir C, 
Gutmann L , et al. Impact of the pneumococcal conjugate 
vaccines on invasive pneumococcal disease in [LOCATION_009], 
2001 -2012. Vaccine. 2015 Jan 3;33(2):[ADDRESS_1141926]: V114 101
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
[Lexau, C. A., et al 
2005]Lexau CA, Ly nfield R, Danila R, Pi[INVESTIGATOR_63466] T, Facklam R, 
Farley  MM, et al. Changing epi[INVESTIGATOR_823565] a mong older adults in the era of 
pediatric pneumococcal conjugate vaccine. JAMA 
2005;294(16):2043 -51.03RBPW
[Liang, K -Y and 
Zeger, S. L. 2000]Liang K -Y, Zeger SL. Longitudinal data anal ysis of 
continuous and discrete responses for pre -post designs. 
Sanky ha: The Indian Journal of Statistics 2000;62(Series B, 
Part 1):134 -48.00V5V6
[Martinelli, D., et 
al 2014]Martinelli D, Pedalino B, Cappelli MG, Caputi G, Sallustio 
A, Fortunato F, et al Towards the 13 -valent pneumococcal 
conjugate universal vaccination: effectiveness in the 
transition era between PCV7 and PCV13 in I taly, 2010 -
2013. Hum Vaccin Immunother. 2014;10(1):33 -9.04KW8B
[Metlay , J. P., et al 
2006]Metlay  JP, Fishman NO, Joffe M, Edelstein PH. Impact of 
pediatric vaccination with pneumococcal con jugate vaccine 
on the risk of bacteremic pneumococcal pneumonia in 
adults. Vaccine 2006;24:468 -75.03RC46
[Moore, M. R., et 
al 2015]Moore MR, L ink-Gelles R, Schaffner W, Ly nfield R, L exau 
C, Bennett NM, et al. Effect of use of 13 -valent 
pneumococcal conj ugate vaccine in children on invasive 
pneumococcal disease in children and adults in the [LOCATION_003]: 
analysis of multisite, population -based surveillance. Lancet 
Infect Dis. 2015 Feb 3. [Epub ahead of print].043MRP
[Palmu, A. A., et al 
2015]Palmu AA, Kilpi [CONTACT_58465], Rinta -Kokko H, Noh ynek H, 
Toropainen M, Nuorti JP, et al. Pneumococcal conjugate 
vaccine and clinicall y suspected invasive pneumococcal 
disease. Pediatrics. 2015 Jul;136(1):e22 -7.04KVRL
[Penaranda, M., et 
al 2010]Penaranda M, Pay eras A, Cambra A, Mila J, Riera M. 
Group. Conjugate and poly saccharide pneumococcal 
vaccines do not improve initial response of the 
polysaccharide vaccine in HIV -infected adults. AIDS. 2010 
May15;24(8):1226 -8.04NRTZ
[Pi[INVESTIGATOR_63466], Tamara, 
et al 2010]Pi[INVESTIGATOR_63466] T, Lexau C, Farle y MM, Hadler J, Harrison L H, 
Bennett NM, et al. Sustained reductions in invasive 
pneumococcal disease in the era of conjugate vaccine. J 
Infect Dis 2010;201(1):32 -41.03R5S4
[Romero -Steiner, 
S., et al 1997]Romero -Steiner S, L ibutti D, Pais LB, Dy kes J, Anderson P, 
Whitin JC, et al. Standardization of an opsonophagocytic 
assay  for the measurement of functional antibod y activity  
against streptococcus pneumoniae using differentiated HL -
60 cells. Clin Diagn Lab Immunol 1997;4(4):[ADDRESS_1141927]: V114 102
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
[Ruckinger, S ., et 
al 2009]Ruckinger S, van der Linden M, Reinert RR, von Kries R, 
Burckhardt F, Siedler A. Reduction in the incidence of 
invasive pneumococcal disease after general vaccination 
with 7 -valent pneumococcal conjugate vaccine in German y. 
Vaccine 2009;27:4 136-41.03QYQQ
[Tomczy k, S., et al 
2014]Tomczy k S, Bennett NM, Stoecker C, Gierke R, Moore 
MR, Whitney  CG, et al. Use of 13 -valent pneumococcal 
conjugate vaccine and 23 -valent pneumococcal 
polysaccharide vaccine among adults aged is greater than or 
equal to 65 y ears: recommendations of the Advisory  
Committee on I mmunization Practices (ACIP). MMWR 
Morb Mortal Wkly  Rep. 2014 Sep 19;63(37):822 -5.040XNF
[U.S. Food and 
Drug 
Administration 
2009]U.S. Food and Drug Administration (CDER, CBER, 
CDRH). Guidance f or industry  patient -reported outcome 
measures: use in medical product development to support 
labeling claims [I nternet]. Washington: U.S. Department of 
Health and Human Services; 2009. Available from: 
https://www.fda.gov/downloads/drugs/guidances/ucm19328
2.pdf04MG9J
[Wagenvoort, G. 
H., et al 2016]Wagenvoort GH, Knol MJ, de Melker HE, Vlaminckx BJ, 
van der Ende A, Rozenbaum  MH, et al.  Risk and outcomes 
of invasive pneumococcal disease in adults with underlying 
conditions in the post -PCV7 era, The Nether lands. Vaccine. 
2016 Jan 12;34(3):334 -40.04KTDB
[Waight, P. A., et 
al 2015]Waight PA, Andrews NJ, L adhani SN, Sheppard CL , Slack 
MP, Miller E. Effect of the 13 -valent pneumococcal 
conjugate vaccine on invasive pneumococcal disease in 
England and Wales 4 years after its introduction: an 
observational cohort study. Lancet Infect Dis. 2015 
May;15(5):535 -43.04KTF2
[Weiss, S., et al 
2015]Weiss S, Falkenhorst G, van der Linden M, Imohl M, von 
Kries R. I mpact of 10 -  and 13 -valent pneumococcal 
conjugate vacc ines on incidence of invasive pneumococcal 
disease in children aged under 16 y ears in [LOCATION_013] , 2009 
to 2012. Euro Surveill. 2015 Mar 12;20(10):[ZIP_CODE].04KTFC
[Whitney , Cynthia 
G., et al 2003]Whitney  CG, Farley  MM, Hadler J, Harrison LH, Bennett 
NM, Ly nfield R, et al. Decline in invasive pneumococcal 
disease after the introduction of protein -polysaccharide 
conjugate vaccine. N Engl J Med 2003;348(18):1737 -46.03QT0D
[World Health 
Organization 
2013]World Health Organization.  Global Update on HIV 
Treatment 2013: Results, I mpact and Opportunities.03RTKT 
  04Y2KD 
  05KG4L
PRODUCT: V114 103
PROTOCOL/AMENDMENT N O.:018-01 
V114 -018-01-FINAL PROTOCOL 01-JUN-2018
[Young, J., et al 
2012]Young J, Psichogiou M, Mey er L, Ay ayi S, Grabar S, Raffi 
F, et al. CD4 cell count and the risk of AIDS or death in 
HIV-Infected adults on combination antiretroviral therap y 
with a su ppressed viral load: a longitudinal cohort study 
from COHERE. PL oS Med. 2012;9(3):e1001194.04NKF6 
  04Y2KD 
  05KG4L